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Ever increasing throughput in chemical analysis is of interest for many 
endeavors including biochemistry, genetics and pharmacology.  One of the most 
prominent areas is drug discovery where combinatorial libraries are screened for 
their activities using biochemical assays.  Although multi-well plate-based 
fluorescence assays are highly successful for high-throughput screening, more 
information rich and label-free assays would be more versatile and offer new 
opportunities for human therapeutics discovery.   In this dissertation, methods 
for improving throughput of electrophoretic and mass spectrometric assays and 
their applications to drug screening will be described. 
A fluorescent hydrolysis assay was first developed for G protein-coupled 
receptors (GPCRs).  This assay utilized capillary electrophoresis (CE) for fast 
determination of GPCR activation and proved to be amenable for 
high-throughput applications.  Throughput of assays of this kind was then 
improved by developing microfluidic chips with up to 36 parallel electrophoresis 
channels each capable of rapid separation.  This system was applied to testing 
for inhibitors of RGS-G Protein interaction.  Further improvement of assay 
throughput was sought by developing a sample introduction interface which 
allowed discrete samples in a two-phase flow to be continuously fed to parallel 
xiii 
CE separation.  The ultimate throughput obtained was no longer limited by the 
time-consuming sample transferring step but only by speed of CE separation.  
In the second approach, mass spectrometry (MS) was explored as an analytical 
method for label-free enzyme assays.  In order to improve the throughput of 
MS-based assays and fully exploit the fast scanning speed of MS, nanoliter of 
sample plugs segmented by air were sequentially infused to a conductive 
nano-electrospray ionization (ESI) emitter tip for fast MS analysis.  
High-throughput screening (HTS) of acetylcholinesterase inhibitors was 






Analytical development for chemical analysis is in the transition from traditional 
expensive and bulky instruments to miniaturized, low-cost and functionally integrated 
devices.  One of the promises offered by these „chip‟-sized devices is automated 
sample processing and high throughput.  Increasing throughput for chemical analysis 
is of great interest and pursued for many endeavors including biochemistry, genetics, 
drug discovery, proteomics, clinical chemistry and pharmacology.  One of the most 
prominent areas where high throughput analysis plays a pivotal role is drug discovery.  
In this case, lead compounds are discovered by testing libraries of candidate 




 of chemical 
entities can be generated for a screening library.  In order to test such a huge number 
of compounds, both assay systems and robotics have evolved over the past two 
decades so that over 100,000 assays can be performed each day.  Such systems are 
considered to be ultrahigh throughput screening (uHTS)
1
.   
 Sample and reagent consumption of screening assays is another key issue for 
high-throughput analysis.  With thousands of assays performed per day, reagent 
2 
consumption can become a significant portion of the R&D cost.  Reagent 
consumption has been largely decreased by miniaturizing the HTS system and 
employing high-density microtiter plate (MTP).  For example, by using 1536-well 
plate which has a working volume of 5 µL/well, a 20-fold decrease in reagent 
consumption and a 16-fold increase in throughput can be achieved compared to 
traditional 96-well plate.  Recently even plates of 9,600 wells with a working 
volume of 0.2 µL/well have been introduced
2
.  However, miniaturization adds to the 




Pipetting and dispensing techniques for MTP-based HTS have been reviewed in 
several articles
3, 4
.  These techniques use different mechanisms such as displacement, 
capillary force and droplet ejection.  Evaporation and adsorption can become a major 
limitation of such techniques.  Also detection schemes that are compatible with MTP 
screening are limited to techniques such as scintillation proximity assays (SPAs), 
fluorescence and luminescence
5-7
.  As powerful as these detection systems are, they 
have relatively low information output.  They always rely on changes in the total 
emitted signals from the sample which would indicate progression of the reactions.  
In most cases, only a single component in the assay, usually the one with special label 
or spectroscopic property, can be monitored.  Also sometimes a suitable indicator or 
label is not readily available which limits the assays that can be performed on MTP.  
Moreover, the overall spectroscopic signal can be skewed due by the presence of 
background matrix which adds uncertainty to interpreting the screening results. 
3 
In considering these limitations, it is apparent that separation techniques may be 
desirable tools to be added to the repertoire of HTS.  For example capillary 
electrophoresis (CE) has useful properties for HTS applications such as high speed, 
high resolution separation, low sample consumption and high mass sensitivity.  In 
the first part of the work presented herein, we demonstrate all the steps necessary for 
applying CE to HTS including assay development (Chapter 2), system miniaturization 
and throughput improvement(Chapter 3), and finally automation (Chapter 4).   
In the later part of the dissertation, use of mass spectrometry (MS) for HTS was 
explored.  MS also offers several useful properties for HTS including rapid analysis 
and label-free detection.  We envision that by employing MS we can further expand 
the applications of HTS.  The throughput of MS has been limited by the rate at 
which samples are delivered to its inlet.  In Chapter 5, a novel sample introduction 
scheme for electrospray ionization MS (ESI-MS) was presented and its application to 
drug screening was demonstrated.  
 
Principles of Capillary Electrophoresis (CE) 
We first developed CE-based HTS; hence its basics are discussed in the next three 
sections.  Ever since Michaelis observed proteins migrate to their isoelectric points 
under an external electric field in 1909
8
, electrophoresis-based separation techniques 
have evolved into a number of different modes.  These include capillary zone 
electrophoresis (CZE) which is also known as free-solution CE (FSCE), micellar 
electrokinetic capillary chromatography (MEKC), capillary isoelectric focusing 
4 
(CIEF), capillary gel electrophoresis (CGE), and capillary electro-chromatography 
(CEC).  The separation path in all these techniques is confined in a capillary that has 
an inner diameter ranging from 5 to 200 µm and a length from 5 to 100 cm.  The 
micro-scale separation space in a capillary can effectively prevent convectional 
distortion of the analyte bands, which is similar to what polyacrylamide or agarose 
does in slab gel electrophoresis (GE).  Furthermore, a capillary format offers 
advantages over traditional gels in that its high surface-to-volume ratio enables 
efficient dissipation of Joule heat thus allowing an electric field up to several 
thousand volts per centimeter to be applied compared to merely 15-40 V/cm for GE.   
 CZE, which is usually referred to as CE, is the simplest yet most widely used 
format of electrophoretic separation in capillary.  In CZE bands of analytes migrate 
in the background electrolyte (BGE) solution when an electric field is applied across 
the capillary.  The speed and direction of analyte migration are governed by two 
phenomena: electrophoresis and electroosmotic flow (EOF).  Electrophoresis is the 
migration of charged particles experiencing an electric field.  Its speed is measured 








where q is the charge of the particle, η is the viscosity of the electrophoresis buffer, r 
is the Stoke‟s radius of the particle.  So the charge-to-size ratio of the analyte 
determines its electrophoretic mobility.  Electroosmotic flow, on the other hand, is 
the result of ionized silanol groups on the inner capillary wall (the charged chemical 
5 
moiety can be different when material other than fused silica is used).  The charged 
silanol groups cause a net positive charge for the bulk electrophoresis buffer and 
under the electric field the bulk solution migrates toward cathode.  The 
electroosmotic mobility (µeo) is described by: 


 eo  
where ε is the permittivity and η is the viscosity of the solution, and ξ is the potential 
in the Helmholtz plane.  So the EOF is dependent on the ξ potential which is 
determined by the ionic properties at the capillary/buffer interface.  The overall 
migration velocity (v) of the analyte is then proportional to the electric field strength 
(E) and given by: 
Ev eo )(    
Since the thickness of the diffusion layer at the capillary/buffer interface is 
negligible compared to the capillary i.d., EOF has a plug-shaped velocity profile 
compared to the parabolic profile of a laminar flow driven by pressure.  This directly 
results in much less band broadening compared to techniques such as HPLC.   
In the ideal situation, when factors such as Joule heating, injected sample plug width 
and adsorption are controlled or inconsequential, diffusion is the only dispersive 













 is the variance of the zone.  As can be seen in the equation, high diffusion 
coefficient, long migration length and slow migration velocity result in wider peaks. 
6 
To measure the efficiency of CZE separation, N, the number of theoretical plates, can 










where µave is the average mobility of the analytes and L is the migration length.  
Since N is proportional to the voltage applied, the highest voltage (V) that can be 
applied without causing significant Joule heating or arcing is always desirable for 
achieving high-efficiency CZE separation.  
 Sample injection for CZE is also of great importance because the size of the 
injected sample plug determines both the separation efficiency/resolution and limit of 
detection (LOD).  Both hydrostatic (such as using pressure or gravity) and 
electrokinetic (applying a voltage for injection) injection schemes are widely used and 
have their respective advantages/disadvantages.  For example hydrostatic injection 
does not cause injection bias based on analyte mobility while electrokinetic injection 
is more suitable for rapid serial injections.  
 Overall when developing CZE separation conditions, an array of factors such as 
properties/concentrations of analytes, separation buffer pH and ionic strength, 
capillary diameter and length, and separation voltage need to optimized to achieve 
high efficiency within reasonable separation time.  Readers can find more detailed 





Capillary Electrophoresis-based Enzyme Assay 
Quantification of enzymatic activity is no longer the pure interest of fundamental 
research in the biochemistry labs; rather it has played an increasingly important role 
in biotechnology, pharmaceutical and clinical development.  For example, abnormal 
enzymatic activities have been implicated in many disease states and those enzymes 
have presented themselves as valuable targets for therapeutic interventions.  While 
photometric and radiochemical methods have been historically used to determine 
enzymatic activity, CE has gained popularity for the same purpose.  CE allows fast 
determination of enzyme kinetics by separating enzymatic product from substrate thus 
eliminating the requirement that the product is distinguishable from the substrate.   
Since Krueger et al. measured endopeptidase Arg-C activity using CE for the first 
time in 1991
10
, hundreds of publications have emerged demonstrating different 
enzyme assays using CE.  These assays can take different formats depending on the 
specific application and enzyme under study.  Broadly there are heterogeneous and 
homogeneous enzyme assays.  In the heterogeneous format, enzyme is usually 
immobilized onto some surface to form an enzyme microreactor.  Mixing and 
reaction occur when solution containing enzyme substrate is passed through and the 
substrate turnover is monitored using CE post-reaction.  This format has the 
advantages of improved enzyme stability and catalytic efficiency.  Homogeneous 
format can be divided into three subcategories: 1. pre-column assay where enzyme 
reaction takes place before CE separation; 2. on-column assay where enzyme and 
substrate are mixed electrophoretically on column, which is also known as 
8 
electrophohretically mediated microanalysis (EMMA)
11, 12
; and 3. post-column assay 
where CE is used to separate a mixture of enzyme substrates before they react with 
the enzyme upon elution.  While the on-column and post-column formats are 
considered on-line assay, their application is limited by their low throughput or 
instrumentation difficulties.  To date pre-column enzyme assays have found the 
widest application and well over 100 enzymes have been characterized using this 
format
13
.  More thorough discussions regarding all three assay formats can be found 
in a review by Glatz
13
.  
 A variety of detection schemes have been implemented for CE-based enzyme 
assays, the most common of which are ultraviolet (UV) absorbance, electrochemical 
(EC) and laser-induced fluorescence (LIF) modes.  UV detection is the most widely 
used because it requires no chemical derivatization and majority of analytes absorb 
somewhere in the UV region.  However it can suffer from background interference 
from either the electrophoresis buffer or sample matrix.  Also since absorbance 
intensity is proportional to the UV light pathlength, the micron-scale diameter of 
capillaries results in inherently low sensitivity of absorbance detection.   
In contrast electrochemical detection is concentration-sensitive so its sensitivity is 
not constrained by the size of the capillary.  Both universal detection using 
conductivity and specific detection using amperometry can be achieved using EC.  
Yet the number of literatures reporting CE-enzyme assay using EC detection has 
remained limited.  This is probably due to the technical difficulties involved in the 
EC electrode fabrication and manipulation and decoupling separation voltage from the 
9 
EC signal output.   
Laser-induced fluorescence detection is quite popular for fluorescent enzyme 
assays.  Due to its low background, LOD down to several tens of molecules has been 
reported on CE
14
.  LIF detection is suitable for CE because its sensitivity is not 
dependent on light pathlength thus allowing small i.d. capillary (5-10 µm) to be used 
for high-efficiency separation.  Unfortunately most analytes are not natively 
fluorescent and this necessitates analyte derivatization (including pre-, on, and 
post-column derivatization) or indirect detection using coupled secondary reactions.  
Pre-column derivatization is the most common method for enzyme assay using 
CE-LIF where the substrate is labeled using a fluorophore before reacting with the 
enzyme.  In fact fluorescent analogues of many enzyme substrates with fluorophores 
of different properties are now commercially available.  However, extreme care must 
be taken when choosing the fluorophore and interpreting the enzyme assay results 
since addition of the bulky fluorophores to the substrate might adversely affect the 
substrate-enzyme interaction and alter the enzymatic kinetics.  
 Not only can CE be performed on single capillary it can also be performed in 
parallel on so-called capillary array electrophoresis (CAE) systems.  While the 
application of these capillary array systems has mainly been limited to DNA 
genotyping and sequencing, enzyme assays have been demonstrated on such systems.  
For example Yeung‟s group demonstrated parallel assays for lactate dehydrogenase 
(LDH) using a custom-built 96-capillary system equipped with a UV-absorbance 
detector
15
.  Similarly Tu et al. used a commercial CAE system from SpectruMedix 
10 
which had 96 parallel capillaries and a LIF detector to measure the activity of 




 Capillary Electrophoresis on Chip 
In 1979 Terry et al. constructed a miniaturized gas chromatography (GC) on a 
5-cm diameter silicon wafer
17
.  Ever since then effort has been put forth by many 
researchers and this trend of miniaturization has promised to revolutionize chemical 
processing and analysis.  People use microfabrication techniques adopted from the 
integrated-circuit manufacturing industry to create features of dimensions in the range 
of micrometers to millimeters on various materials such as silicon, glass and various 
polymers.  These microfabrication techniques have been covered and discussed in 
several reviews
18-20
.  Microfabrication not only creates analytical devices with 
significantly decreased footprint but also enables integrating all sorts of laboratory 
functions on a single device.  These microfabricated devices are named 
microelectromechanical systems (MEMS) or micro-total analysis systems (µTAS) 
which are also known as lab-on-a-chip.   
CE was first demonstrated on chip by Manz et al. in 1991
21
.  To date CE is the 
dominant separation function that is applied to chips probably because the compatible 
dimension of microfabricated channels.  A plethora of chemical analyses have been 
demonstrated using CE on chip including DNA, protein and small molecule analysis
22, 
23
.  CE-based enzyme assays, which have been performed extensively on capillary as 








 assays have all be demonstrated on chip. 
Microfabricated electrophoresis devices are mainly fabricated on glass due to its 
suitable surface chemistry (high density of negatively charged silanol groups) and 
optical transparency.  As an alternative material, polymers have gained increasing 
popularity because of their tunable surface characteristics and potential for low-cost 
mass production.  However, separation efficiency comparable to CE on glass chips 
has yet to be demonstrated.   
Compared with traditional CE, CE on chip has a lot more advantages besides the 
small size.  For example shorter separation channels (down to several millimeters) 
can be constructed on chip allowing extremely fast separation (sub-second separation).  
Sample injection on chip also allows flexible and fine control to allow shorter 
injection plug.  But probably the biggest advantage about performing CE on chip is 
that multiple CE separation units can be fabricated on a single wafer without 
significantly increasing production cost and device size.  Relatively simple detection 
schemes are also available compared to those of the capillary-array systems
30, 31
. 
Using such microfabricated electrophoresis channel-array devices multiple 
samples can be electrophoretically analyzed simultaneously allowing proportionally 
improved sample throughput.  Over the past 20 years or so, the number of 
electrophoresis channels integrated on a single device has seen a dramatic increase.  
One key to fabricating such devices is how to arrange the separation channels (Figure 
1-1).  Radial design introduced by Mathies‟s group has produced the highest channel 
density so far by effectively utilizing the wafer surface area.  Eight times more 
12 
channels were fit onto a glass wafer with only a four-fold increase in the wafer size 
(Figure 1-1 B and C).  A four-color rotary confocal scanner was used for 
fluorescence detection of all channels.  Parallel genotyping was demonstrated using 
CGE and 384 DNA samples were analyzed in 325 s.   The highest number of 
separation channels that have been integrated on a single chip was reported by Aborn 
et al (Figure 1-1 D).  However, this arrangement did not have as high channel 
density as that achieved with the radial design.  Similar parallel operations for other 
purposes such as immunoassay have also been reported but in relatively limited 
number of publications
31-34





 and serine/threonine kinase
37
; 





Figure 1-1. Geometric arrangement of electrophoresis channel arrays.  A. 
Parallel arrangement of five separation channels (1994)
38
; B. 48 separation channels 
on a 10-cm-diameter wafer (1998)
39
; C. 384 separation channels on a 20-cm-diameter 
wafer (2000)
40




Since our research goal was to apply the developed analytical techniques to drug 
screening, two of the drug targets we studied and their related biochemistry were 
discussed in the next two parts. 
 
14 
Drug Targets Along the G Protein Signaling Pathway 
Due to the prevalence of G protein signaling in cellular functions, derangement of 
G protein signaling is thought to be involved in a wide range of diseases such as 
diabetes, depression, cardiovascular defects and certain forms of cancer
42
.  Therefore 
therapeutic interventions have hence been sought on these bases.  In view of the 
significance of G protein signaling, we have developed assays for different aspects of 
this pathway as a model system.  
G proteins, short for guanine nucleotide-binding proteins, are a family of proteins 
involved in many intracellular signaling pathways (Figure 1-2)
43
.  They act as 
molecular switches controlling magnitude of signal transductions.  There are two 
distinct families of G proteins: heterotrimeric and Ras G proteins.  As the name 
suggests heterotrimeric G protein is made up of three subunits: α, β and γ.  Ras 
proteins, on the other hand, are monomeric and are homologous to the α subunit of 
heterotrimeric G protein.  In the work presented here we will refer to heterotrimeric 
G proteins as G proteins.  G proteins can alternate between two states: when the α 
subunit binds to guanosine diphosphate (GDP) α, β and γ form an inactive trimer; 
when GDP is replaced by guanosine triphosphate (GTP), α subunit disassociates from 
β/γ dimer and both of them can interact with downstream effectors such as adenylyl 
cyclase, protein kinase and phospholipase and activate signaling cascades
44
.  
Conversion between these two states is mediated by G protein-coupled receptors 
(GPCRs).  When an extracellular ligand binds to GPCR it can induce enough 
conformation change in the receptor which allows the receptor to function as so-called 
15 
guanine nucleotide exchange factor (GEF).  Activation of GPCR then leads to 
GPCR-G protein coupling and activation of G protein.  G protein signaling continues 
after activation until GTP bound to the α subunit is hydrolyzed to GDP by the intrinsic 
GTPase activity of the α subunit.  A variety of intracellular proteins further 
accelerate this hydrolysis process (turning-off of the signaling) and are classified as 
GTPase-activating proteins (GAPs).  RGS proteins, or regulators of G 
protein-signaling, is one such GAP.  By stabilizing the G protein-GTP transition state 
during hydrolysis RGS proteins markedly reduce the lifetime of activated α subunit 
and attenuate the signaling
45
.   
 
Figure 1-2. The G-protein activation/deactivation cycle. 1. The agonist–receptor 
interaction promotes a series of conformational changes favoring receptor coupling to 
G protein(s); 2. Formation of the agonist–receptor–G-protein ternary complex 
promotes a G-protein conformational change facilitating; 3. The exchange of 
α-subunit-bound GDP for GTP; 4. the activated G protein then dissociates to form the 
GTP-bound α subunit and the βγ complex.  The GTP-bound α subunit and βγ 
complex regulate the activity of specific intracellular effector proteins, leading to 
changes in the levels of secondary messengers (e.g. cAMP and calcium) and 
regulation of select signal transduction pathways; 5. The activity of the GTP-bound α 
subunit is terminated by hydrolysis of GTP to GDP by intrinsic GTPase activity of the 
α subunit; 6. The cycle is completed through the reassociation of the GDP-bound α 
subunit with the βγ complex. The kinetics of the G-protein activation/deactivation 
cycle are modulated by several accessory proteins including regulators of G-protein 
signaling (RGS) proteins
3





 GPCRs, encoded by the largest gene family (800-1000 GPCR genes
46
) in human 
genome, interact with a variety of ligands such as biogenic amines, amino acids, ions, 
peptides and proteins
47
.  GPCRs are one of the most studied drug targets in modern 
pharmaceutical research, and over 50% of clinically used drugs target GPCRs
48
.  
Desire to discover more effective and specific GPCR drugs, including drugs targeting 
those some 150 orphan GPCRs whose functions are unknown, remains to the driving 
force behind the development of more efficient, robust and cost-effective GPCR 
assays.  Historically GPCR drug screening has focused on identifying compounds 
that bind to a receptor typically through displacement of a known ligand.  
Limitations of this approach include requirement of having a known ligand to start 
with (i.e., cannot be applied to drug screening for orphan GPCRs) and lack of 
quantification of GPCR activation.  Functional assay has been replacing binding 
assay and a variety of platforms have been developed and even commercialized
43
.  
There are mainly two categories of GPCR functional assays: proximal point (directly 
reporting GPCR activation as a function of G protein activation) and distal point 
(measuring downstream secondary messengers such as cAMP, inositol phosphate and 
calcium levels).  Proximal point assays can reduce the incidence of false positives; 




P]GTP are usually 
used, imposing high cost and environmental hazards.  A non-radioactive GTP 
analogue (europium-labeled GTP) has been introduced by Perkin Elmer to allow 
time-resolved fluorescence (TRF) binding assay.  However all these assays require 
tedious filtration and are time-consuming, hence are not suitable for HTS.  Distal 
17 
point assays have the benefit of amplified signal but suffer from false positives 
associated with stimulation of the secondary messengers independent of the GPCR.  
Actually several distal point assay kits have been commercialized and instruments 
such as fluorometric imaging plate reader (FLIPR) can be used for detection allowing 
HTS.  However, these assays sometimes require modification of G proteins so that 
the GPCR can be coupled to a pre-selected second messenger system; thus response 
may not be representative of the in vivo signal pathway.  In all an ideal GPCR assay 
should be simple, non-radioactive, reliable, homogenous and amenable to HTS.  In 
Chapter 2, we developed such an assay based on fast CE separation and effects of 
GPCR drugs were successfully detected. 
RGS proteins have recently emerged as an attractive drug target.  These proteins 
have been implicated in diseases such as Alzheimer‟s, Parkinson‟s, epilepsy and 
depression
49
.  Since RGS proteins accelerate GTPase activity, inhibitors of RGS can 
enhance G protein signaling and promise to potentiate GPCR agonists.  Also the 
highly localized and dynamically regulated distribution of RGS proteins means that 
RGS protein drugs should have high specificity and low side effects
50
.  However 
lack of high-throughput assays for RGS protein activity is hampering the rate of 
discovery of RGS inhibitors.  Single-turnover hydrolysis assay using [γ-
32
P]GTP is 
the most widely used assay for RGS functions
51
.  To eliminate the requirement of 
radiolabeled chemical, a stopped-flow spectroscopic assay has been developed by the 
Neubig group
52
.  This assay measures decrease of the intrinsic tryptophan 
fluorescence of G protein α subunit accompanying GTP hydrolysis allowing 
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millisecond-kinetics to be monitored.  Yet this assay has not been applied to HTS.  
Flow cytometry protein interaction assay (FCPIA) based on RGS-G protein binding 
has been developed for identifying small molecule RGS inhibitors
53
.  Commercial 
Luminex 100IS 96-well plate reading flow cytometer used in this study allows 
analyzing a 96-well plate in less than 30 min.  Since binding results can not be 
directly translated to information regarding functional modulation, FCPIA is 
susceptible to false positives and negatives and additional confirmation of inhibitor 
activity is required.  More recently, Jameson et al. developed a CE-LIF-based 
hydrolysis assay where a fluorescent GTP analogue, BODIPY
®
 FL GTP (BGTP), was 
used to determine GTPase activity modulated by RGS proteins
54
.  This functional 
assay showed promises to be used for HTS for RGS inhibitors.  In Chapter 3, we 
increased the throughput of this assay by performing parallel CE on chip.  Up to 36 
assay reactions could be analyzed simultaneously.  
 
Acetylcholinesterase as Drug Target 
Acetylcholinesterase (AchE) is another important drug target that was explored in 
this work.  It is present in cholinergic neurons playing a pivotal role in controlling 
cholinergic signal transduction by catalyzing the hydrolysis of acetylcholine (Ach) to 
its inactive product choline.  Ach is an important neurotransmitter that carries nerve 
impulses across the cholinergic pathway.  Based on the so-called cholinergic 
hypothesis
55-57
, depletion of Ach in the synaptic cleft can be associated with 
Alzheimer‟s disease (AD), the most common neurologic disorder among aged 
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population.  AchE inhibitors which prolong lifetime of Ach in the brain are currently 
be sought as potential treatment for AD
58, 59
.  While a handful of AchE inhibitors 
have been approved for AD treatment, searching for compounds with improved 
pharmacological and toxicological properties remains to be of great importance
60-63
.  
The most widely used assay for AchE activity is based on a photometric method 
developed by Ellman et al
64
.  Inhibitor screening based on this method has been 
demonstrated.  For example, flow injection analysis (FIA) coupled to immobilized 
enzyme columns with UV detection was used for fast inhibitor screening at about 1 
sample per 10 minutes
65, 66, 67







 assays have also been reported.  However, either a 
fluorogenic substrate or a secondary reaction was used in these methods.  This tends 
to cause false positives and negatives in the screening process.  Mass spectrometry 
has been used to detect AchE inhibitors where unlabeled Ach was used.  Hu et al. 
used immobilized AchE microspheres for AchE inhibitor detection
71
.  Hydrolysis 
was quenched by removing the magnetic microspheres before ESI-MS analysis.  
Ozbal et al used a microfluidic system integrating on-line HPLC sample purification 
and ESI-MS for AchE inhibitor screening
72
.  Highly sophisticated robotic system 
was used for flow injecting of individual samples and a throughput of 4-5 s per 
sample was achieved.  
 
Sub-microliter Liquid Handing and Segmented Flow 
As discussed earlier, multi-well plates are the main platform for HTS, and well 
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plates of increasing density are used to increase screening throughput and reduce cost 
of reagents.  However, expensive robotics and sophisticated techniques are required 
for reagent dispensing and these approaches are limited by evaporation and surface 
tension.  Confining nanoliter sample plugs segmented by gas or immiscible liquid 
has recently emerged as a promising alternative to well plate-based screening
73
. 
Three ways to generate such segmented flow are illustrated in Figure 1-3 A-C.  
These discrete sample plugs or droplets act as miniaturized reaction vessels and they 
can be manipulated automatically in a high-throughput fashion.  A full spectrum of 











 have been demonstrated (Figure 1-3 D).  A variety of 







 and protein crystallization
83
.  However, methods 
for chemically analyzing droplets have been largely limited to those optical methods 
such as fluorescence and X-ray diffraction.  For example, a droplet-based 
fluorescence assay was develop for screening phosphatase activity of several 
proteins
84
.  Also screening for protein crystallization conditions using x-ray 
diffraction was also demonstrated
83







 have also been explored for droplet 
analysis.  Off-line collection and analysis of droplets by MALDI was demonstrated 
for screening organic reactions in droplets
82
.  Also on-line extraction of droplets 
using microfluidic chip for CE and MS analysis was demonstrated by several 
groups
86-88
.  It can be envisioned that combining enzyme assay in droplets with fast 
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and information-rich analytical techniques will open up new possibilities for HTS.  
In Chapter 4, we used segmented flow as a sample introduction tool and coupled it to 





Figure 1-3. Examples of microfluidic droplet generation and manipulation.  A. 
Generating droplets by sampling from a 96-well plate.  Inlets of the tubing are 
inserted into sample and oil alternatively
90
; B. Droplet generation using a T-junction.  
Either oil (a) or gas (b) can be used as the immiscible phase.  Aqueous sample 
breaks off from the T-junction and forms droplet
91
; C. Droplet generation using a 
flow-focusing geometry.  Aqueous sample is pushed through a small orifice to form 
droplet emulsion
92
; D. Fast mixing using chaotic advection after reagent addition.  




HTS using Mass Spectrometry 
Assays based on the spectroscopic properties of analytes usually require the use 
of surrogate substrates or secondary reactions to produce detectable signals such as 
fluorescence.  This can sometimes cause false reflection of enzyme activity (e.g. in 
enzyme assay) and produce false positives or negatives.  Mass spectrometery 
22 
(MS)-based assays are an interesting alternative in this regard in that no labeling is 
required and native substrates or binding partners can be used
93
.  Screening using 
MS generally falls into one of two categories: testing one compound at one time or 
testing all compounds at once (also known as one-pot screening)
94, 95
.   
The one-pot strategy is exclusively used for testing affinity interactions between 
test compounds and the target.  The entire pool of combinatorial compounds are 
usually mixed with and competitively bind to the target protein before the 
non-covalent complexes and unbound species are separated and detected
96
.  Various 
separation techniques can be used to separate the complexes from the unbound before 







 and frontal affinity chromatography
100, 101
.  Stand-alone MS, termed 
bioaffinity MS, can also be used for screening affinity interactions without prior 
separation and achieving higher throughput
102, 103
.  Non-covalent complexes are 
selected for fragmentation in tandem MS and bound ligands are then detected.  
Testing individual compounds is more common for screening combinatorial 
libraries.  Assay reactions are performed in individual wells containing the test 
compounds prior to MS analysis.  Effects of compounds on both protein-protein 
interactions and enzyme activities can be tested this way.  However, it requires 
pipetting individual samples and rinsing after each analysis and this limits the overall 
throughput.  Multiplexed CE and HPLC have been employed and coupled to MS to 
process multiple samples simultaneously
15, 58, 72, 104
; however, the throughput still falls 
short of HTS needs.  In Chapter 5, we again used segmented flow as the sample 
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introduction method and coupled it to ESI-MS.  We demonstrated label-free inhibitor 
screening for acetylcholinesterase and throughput as high as 0.65 Hz was achieved
24 
CHAPTER 2 
CAPILLARY ELECTROPHORESIS ASSAY FOR G PROTEIN-COUPLED 
RECEPTOR-MEDIATED GTPASE ACTIVITY 
Reproduced in part from (Jameson, Pei et al. 2007). Copyright 2007 American Chemical Society 
 
Introduction 
Heterotrimeric guanine nucleotide binding proteins (G proteins) play an 
important role in intracellular signaling pathways by coupling membrane bound 
receptors (G protein-coupled receptors or GPCRs) to downstream effectors.  The G 
protein α subunit (Gα) switches from an inactive (GDP-bound) to an active 
(GTP-bound) form in response to agonist binding to GPCR.  Signaling is terminated 
when the G protein, which is a GTPase, hydrolyzes bound GTP to GDP.  G protein 
pathways regulate many processes related to cardiovascular, neural, and endocrine 
function, and as such an intense focus has been placed on the development of GPCRs 




GPCR drug screening has historically focused on identifying compounds that 
bind to a receptor (typically through displacement of a known ligand), followed by 
functional assays to detect effects on downstream effectors or second messengers 
associated with the GPCR.  Limitations of this approach include requirements of
25 
having a known ligand to start and the use of radiolabeled species for the assays.  
The drive to screen based on functional response, along with concerns associated with 
the use of radioactivity, led to the development of whole cell, fluorescence-based 
assays.  In these assays, G protein activation via the GPCR evokes a chemical 
change (such as intracellular Ca
2+
 concentration) that can be conveniently monitored 
using an appropriate instrument such as a Fluorometric Imaging Plate Reader (FLIPR) 
106
.  However, these whole-cell assays sometimes require modification of G proteins 
so that the GPCR can be coupled to a pre-selected second messenger system; thus 
response may not be representative of the in vivo signal pathway.  These assays are 
also subject to false positives associated with stimulation of the second messenger 
independent of the GPCR.  Finally, it can be difficult to detect modulation of GPCR 
signal downstream of the ligand binding. 
A significant goal for GPCR screening therefore remains the development of 
non-radioactive assays capable of reporting GPCR activation directly as a function of 
GTP binding or GTPase activity using G proteins that maintain their in vivo coupling 
specificities.  Progress has been made in the first goal by development of Eu-GTP, a 
non-hydrolyzable GTP analogue that exhibits fluorescence changes upon binding to G 
proteins
107
.  This reagent has formed the basis of numerous assays for GPCR 
screening at the level of GTP binding
108
.  Screening at the hydrolysis step is also of 
interest because of the potentiality of modulating hydrolysis for modulating activity of 
GPCRs.  Fluorescent probes for the hydrolysis reaction have also been 
investigated
109, 110
.  One intriguing example has been the use of the fluorescent GTP 
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analogue, BODIPY  FL GTP (BGTP) as a reporter substrate.  Although there have 
been no reported differences in fluorescence properties of BGTP and the hydrolyzed 
form BODIPY  GDP (BGDP), it has been shown that the protein-bound forms have 
significant differences in fluorescence intensity
110
.  Thus, under conditions where all 
the BODIPY-labeled nucleotide is bound (i.e., a single turnover assay), it is possible 
to record fluorescence changes from hydrolysis.  The assays that were developed 
based on these fluorophores however were not extended to membrane preparations 
and therefore could not be used to detect a GPCR-mediated effect on GTPase activity; 
rather they were designed to investigate biochemical mechanisms that do not involve 
the membrane-bound receptor.  Although it may be possible to extend these assays to 
membrane systems, several factors could make this difficult including nonspecific 
binding of BGTP to the membrane preparation components and the requirement of 
working under single turnover conditions. 
Another approach to performing enzyme assays is by capillary electrophoresis 
with laser-induced fluorescence (CE-LIF) as recently reviewed
13, 111
.  Two 
advantages of CE-LIF for enzyme assays that are relevant to this application are (1) 
the substrate and product can be separated, thus eliminating the requirement for a 
fluorescence difference between the two, and (2) the development of parallel CE-LIF 
instrumentation suggests the potential for high-throughput screening as demonstrated 
for other enzyme assay systems
15
.  Previously, we have demonstrated that CE-LIF 
assays can be successfully employed to determine the GTPase activity of purified G 
proteins with a fluorescent GTP analogue, BGTP, as the substrate
112
.  On the basis of 
27 
this result, we hypothesized that GPCR-mediated GTPase activity could also be 
detected using BGTP as substrate and CE-LIF as a read-out to yield a new approach 
to screen for drugs that modulate GPCRs.  Herein, we describe such an assay and 
demonstrate that it is simple, rapid, automatable, and yields results similar to those 






H]-Yohimbine (80.5 Ci/mmol) was from Perkin-Elmer Life Sciences (Boston, 
MA).  Lipofectamine 2000 was from Invitrogen (Carlsbad, CA).  BGTP and BGDP 
were obtained from Molecular Probes (Eugene, OR).  10× Tris-glycine buffer was 
purchased from Bio-Rad Laboratories (Hercules, CA). Enzyme-grade sodium 
phosphate monobasic was purchased from Fisher (Fair Lawn, NJ).  All other 
chemicals were from Sigma Chemical Co. (St.Louis, MO).  RGS8 was expressed 
and purified as previously described
113, 114
 and stored at −80 °C until used.  Buffers 
were made with deionized water purified by an E-Pure water system (Barnestead 
International Co., Dubuque, IA) and filtered prior to use. 
 
Construction of α2A-Adrenergic Receptor-Gαo Fusion Plasmids, Cell Culture, and 
Transfection  
Wild-type (wt) α2A adrenoreceptor-Gαo1 (α2AAR-Gαo1) fusion plasmid and 
α2AAR-Gαo1 C351I fusion plasmid (with a 351Cys→Ile mutation on Gαo1) were 
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constructed as previously described
115
.  HEK293T cells were maintained at 37 °C in 
5% CO2 in DMEM medium with 10% fetal bovine serum, 100 U/mL penicillin, and 
100 μg/mL streptomycin.  Cells were transiently transfected with either the α2A-Gαo1 
fusion (wt) or α2A-Gαo1 C351I fusion (C351I) for 48 h using 10 μg of plasmid DNA 
and 30 μL of lipofectamine 2000 per 100 mm dish according to the manufacturer's 
instructions. 
 
Membrane Preparation  
Transfected HEK293T cells were lysed at 4 °C for 15 min in 1 mM Tris, pH 7.4, 
with 10 mM benzamidine, 1 μg/mL aprotinin, and 1 mM PMSF.  Cell membranes 
were homogenized with 10 strokes using a Potter−Elvehjem tissue grinder.  Nuclei 
and undisrupted cells were removed via centrifugation by a 10 min, 4 °C spin at 
1000g.  The supernatant was reserved. The pellet was resuspended in buffer, 
homogenized, and spun as above.  The two supernatants were then combined.  The 
membrane fraction was pelleted with a 30 min spin at 40000g at 4 °C.  The pellet 
containing membrane was resuspended in 50 mM Tris, 10 mM MgCl2, 1 mM EGTA, 
pH 7.6, with protease inhibitor (Roche Complete, Mini).  Aliquots were snap frozen 
in liquid nitrogen and stored at −80 °C until use.  Membrane protein content was 
determined via a Bradford assay (Bio-Rad, Hercules, CA).  [
3
H]-Yohimbine binding 
assays were performed on 10 μg of membrane protein in a final volume of 100 μL as 
previously described
116
.  The results of these assays for both fusion preparations are 
as follows: wt, 1.565 mg of protein/mL, 2.9 pmol of α2A receptor/mg of protein; 
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C351I, 1.465 mg of protein/mL, 3.2 pmol of α2A receptor/mg of protein. 
Capillary Electrophoresis Instrumentation  
At the beginning of each day, the separation capillary was rinsed with 1 M NaOH, 
deionized water, and electrophoresis buffer for 2 min each.  For rapid CE separations, 
a CE-LIF instrument equipped with “flow-gated” injection similar to that described 
elsewhere was used
117, 118
.  Briefly, the sample was loaded into a chamber that was 
then pressurized so that sample flowed from the chamber to the flow-gate interface 
through a fused-silica capillary (Polymicro Technologies, Phoenix, AZ).  The 
flow-gate controlled periodic injections (details below) onto the CE-LIF where 
sample was rapidly separated.  Electrophoresis buffer was supplied as a gating-flow 
at 1.2 mL/min by a series I HPLC pump (LabAlliance, Fisher Scientific, Pittsburgh, 
PA) equipped with an external pulse dampener. 
When the valve on the flow-gate line was open, electrophoresis buffer flowing 
through the flow-gate caused the sample to be washed to waste.  To inject sample 
onto the electrophoresis capillary, the valve was closed so that buffer flow stopped, 
allowing sample to accumulate in the interface between the two capillaries.  The 
injection voltage was then applied across the separation capillary by a high-voltage 
power supply (CZE 1000R, Spellman High Voltage Electronics, Plainview, NY) for a 
specified amount of time to load sample onto the capillary column.  Once sample 
was injected, gating-flow of electrophoresis buffer was resumed by actuating the 
gating valve, and separation voltage was applied.  Serial injections could be 
performed at a rate limited by separation time.  All operations were controlled by a 
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personal computer equipped with a multi-function board (AT-MIO-16, National 
Instruments, Austin, TX) using software written in-house. 
Detection was accomplished using LIF as described elsewhere
119
.  The LIF 
detector used the 488-nm line of an air-cooled 15 mW Ar
+
 laser (Spectra Physics, 
Mountain View, CA) as the excitation source.  Fluorescence was collected 90
°
 from 
the excitation source via a 40× microscope objective (Melles Griot, Irvine, CA).  
The fluorescence emission was spectrally filtered using a 520 ± 10 nm band-pass 
filter and a 488 nm notch filter (Corion, Holliston, MA), and spatially filtered through 
two pinholes (5 mm × 7 mm and 1.5 mm × 4 mm) before entering a photomultiplier 
tube (PMT) (model E717-21, Hamamatsu Photonics, Bridgewater, NJ).  Signal from 
the PMT was amplified by a Keithley 428 current amplifier and collected using the 
same computer and software used for instrument control.  Processing of 





For most of the BGTP assays, the electrophoresis buffer was 75% 25 mM Tris, 
192 mM glycine pH 8.5, and 25% 100 mM sodium phosphate pH 7.1 (TGP).  
Samples were prepared in 50 mM Tris-HCl, pH 7.4 buffer supplemented with 1 mM 
EDTA, 5 mM MgCl2, 1 mM DTT, 100 mM NaCl, and 10 μM GDP.  All experiments 
were performed at room temperature (RT). 
 
GTPase Assays  
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Samples containing 58.6 fmol of α2A receptor (fused to either wt or C351I Gαo1) 
in HEK293T membranes, 1 μM BGTP, 12.8 nM rhodamine 110 as the internal 
standard (IS), and indicated levels of UK14,304 (0.1 nM−0.4 mM), with and without 
300 nM yohimbine were incubated in a total volume of 50 μL for 10 min at RT. 
Following incubation, membranes were removed from samples using 10 kDa MWCO 
Micron Centrifugal Filter Devices (Millipore Corporation, Bedford, MA) that had 
been rinsed three times with 50 μL of deionized water for 10 min at 13.4k rpm. 
Samples were spun at 13.4k rpm for 10 min, and the filtrate was analyzed by CE-LIF. 
Experiments with RGS were performed in a similar manner, with either 1.3 μM or 5.2 
μM RGS8 added concomitant with the other sample components. 
In some experiments, the filtration step was bypassed for a direct injection assay. 
In these experiments, 0.6 μg of membrane containing 6.8 fmol of receptor was 
incubated with the same buffer as the GTPase assay modified to contain 0.53 mM 
adenosine 3,5‟-(β,γ-imino)triphosphate (App(NH)p).  After 10 min of incubation, the 
samples were pumped into the flow-gated interface, without filtration.  Separation 
was performed as for the GTPase assay except the electrophoresis buffer was 25 mM 
Tris, 192 mM glycine, and 1.5 mM MgSO4 adjusted to pH 8.5. 
The extent of BGDP product formation in each sample was assessed using the 
ratio of the peak areas of BGDP and IS (BGDP/IS).  Conversion to BGDP 
concentration was made by comparison to an external calibration curve generated 
from standards (i.e., non-membrane containing samples) with various BGDP/IS ratios 
where the BGDP was varied over the range of expected concentrations.  For all 
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samples, the BGDP/IS ratio was determined by averaging the data from 10 individual 
electropherograms. 
Dose−response curves are reported as specific GTPase activity versus drug 
concentration.  For this calculation, the concentration of total BGDP formed was 
measured for each drug concentration using the conditions above.  The BGDP 
produced as a result of the specific (low KM) GTPase activity was calculated by 
subtracting the BGDP due to nonspecific GTPase (high KM) from the total BGDP 
formed.  Nonspecific GTPase activity was determined by adding 10 μM GTP to a 
membrane incubation mixture in the absence of drug and recording the amount of 
BGDP formed.  This background value was used for all subsequent assays on a 
given day. The fluorescence signal attributed to specific GTPase activity was 




.  Complete dose−response 
curves were obtained 3 times each in the presence and absence of the antagonist 
yohimbine.  Averaged dose−response data were fit to sigmoidal curves using 
GraphPad Prism 3.0 (GraphPad Software, San Diego, CA).  Statistics calculations 
were also performed with GraphPad Prism, using a two-tailed t test.  All data are 
reported as the mean ± SD. 
 
Results and Discussion 
Overview of GPCR Activation Assay  
The principle of the CE-LIF assay is illustrated in Figure 2-1.  Membranes 
expressing the α2AAR-Gαo1 fusion proteins were incubated in solution containing 
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GPCR ligand, 1 μM BGTP, and an internal standard (IS) for 10 min at RT.  The 
BGTP hydrolysis reaction was subsequently quenched by removal of membranes 
from the sample via rapid filtering through a 10 kDa molecular weight cutoff filter. 
CE-LIF was used to separate BGTP (G protein substrate) from BGDP (product of G 
protein GTPase activity) in the resulting filtrate, allowing detection of 
agonist-stimulated activity based on the increase in hydrolysis product formation. 
Typical electropherograms from sample with (right) and without (left) the α2A 
receptor agonist UK14,304 are shown in Figure 2-1, demonstrating both the complete 
separation of all fluorescent components (IS, BGDP, and BGTP) as well as the 
increase of BGDP formation observed in the sample containing agonist.  The CE 
separation step was a vital component of the assay, as fluorescence of the BGDP 
product is equivalent to that of the BGTP substrate (data not shown), meaning that no 
change would be observed if only total fluorescence had been monitored.  Two 
electrophoretic peaks each are observed for BGDP and BGTP as BGTP is supplied as 
a mixture of the 2‟ and 3‟-isomers.  In agreement with previous studies using 







































Figure 2-1. CE-based fluorescence assay for receptor-mediated G protein 
GTPase activity in cell membranes.  The cartoon portion illustrates the hydrolysis 
of BODIPY FL GTP (BGTP) to BODIPY FL GDP (BGDP) by heterotrimeric G 
proteins in a sample containing cell membranes with (right) and without (left) GPCR 
ligand (in this case an agonist).  The electropherograms (actual data) show how the 
fluorescent product BGDP is separated from the substrate BGTP by capillary 
electrophoresis (CE), with more BGDP produced in the sample containing agonist. 
Two peaks are observed for both BGTP and BGDP, due to the location of the 
fluorophore on either the 2‟ or 3‟ position of the ribose ring of the GTP substrate. 
 
Agonist-stimulated hydrolysis of BGTP was measured in membranes expressing 
the α2AAR fused to wt Gαo1 or Gαo1 with a 351Cys→Ile mutation (C351I Gαo1). 
GPCR−Gα fusion systems were chosen for these studies as they typically translate 
into highly reproducible assays due to the defined 1:1 stoichiometry and ensured 
physical proximity of the signaling partners
105
.  An added advantage is that the 
extent of nucleotide binding in the presence of agonist is significantly elevated in 
fusion systems as compared to unfused co-expressed receptors and Gα subunits.  The 
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use of Gαo1 with the 351Cys→Ile mutation has been shown to further enhance GTP 




Dose−Response Curves of Specific Activity  
For quantification, the amount of BGDP produced in each sample was calculated 
from a calibration curve using the ratio of the sum of the two BGDP peak areas to the 
peak area of IS (BGDP/IS) as the signal.  The calibration curve was constructed 
using BGDP standards prepared in the same buffer used for the assay, including IS, 
and a range of BGDP concentrations that spanned the concentrations generated by the 
assay.  This method of calibration accounted for any effects of the assay buffer on 
separation and detection and ensured a response in the linear range allowing accurate 
determination of the BGDP produced in any of the membrane preparations used. 
(Effects of minor components, such as the drugs and GTP added to some preparations, 
on the calibration are negligible in CE-LIF measurements allowing the same BGDP 
calibration curve to be used for all samples.) 
Figure 2-1 illustrates that although agonist induces an increase in BGDP 
formation, substantial GTPase activity is detectable without agonist (see BDGP 
formed without drug in left trace of Figure 2-1).  This BGTP turn over occurs 
because tissue and cell lysate samples contain significant GTPase activity that is not 
due to G protein GTPase and is therefore not coupled to the GPCR.  Similar 
background or nonspecific GTPase activity is observed with radiolabeled GTP
122
.  
To account for this nonspecific GTPase activity, radiochemical assays utilize a 
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background subtraction method.  This background subtraction method takes 
advantage of the fact that G protein GTPases have high affinity (i.e., low KM of 0.1 
μM) whereas the nonspecific GTPases have low affinity (i.e., higher KM > 1 μM).  
Therefore, GTPase activity measured the presence of micromolar unlabeled GTP 
(which should block turnover of nucleotide by G proteins) is deemed a result of the 
high KM, nonspecific GTPase and is subtracted from the observed GTPase levels in 
all other samples.  In this way, the low KM GTPase associated with G proteins can be 
probed separately from all other GTPases.  This same background subtraction 
method was used for the CE assays.  Thus, to quantify the G protein-specific GTPase 
activity in the membrane samples, BGDP formed in a sample with 10 μM GTP added 
(but no drug) was subtracted from all subsequent measurements (see Experimental 
Procedures) to determine the specific GTPase activity. 
The specific GTPase activity measured by this assay increased sigmoidally with 
the log of the concentration of α2AAR agonist (UK14,304) added to the membranes 
expressing α2AAR-C351I fusion, as expected for a classical agonist-induced effect 
(Figure 2-2).  The observed EC50 (480 ± 200 nM) was in good agreement with a 
previously reported estimate of 207 ± 8 nM obtained under similar experimental 
conditions with radiolabeled GTP
123
.  Maximal specific stimulation observed with 
UK14,304 was to 525% of basal levels.  Without subtraction of nonspecific activity, 
maximum stimulation was to 125% of basal levels.  The low percent stimulation 
without subtraction of nonspecific activity affirms the importance of probing G 
protein GTPase separately from total GTPase when designing high-sensitivity GPCR 
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activation assays.  In the presence of the α2 antagonist yohimbine, the magnitude of 
observed stimulated BGTP hydrolysis was not affected (525% of basal) but the EC50 
for UK14,304 was shifted to the right, increasing to 9.4 ± 5 μM as expected.  These 
results indicate that GPCR activation can be accurately assessed via hydrolysis of 
BGTP.  These results also demonstrate that both agonists and antagonists can be 
detected. 































Figure 2-2. Dose response curves for UK14,304 in the absence (control) and 
presence of α2AAR antagonist yohimbine. Data shown are for membranes 
expressing C351I fusion protein.  The calculated EC50 values were 480 ± 200 nM (n 
= 3) and 9.4 ± 5 μM (n = 3) for the control and yohimbine experiments, respectively. 
Both data sets were normalized to percent maximal response.  Error bars are ± 1 SD. 
 
Two control experiments were used to ensure that the observed BGTPase activity 
was due to specific (i.e., receptor-mediated) agonist stimulated effects.  In the first, 
similar experiments were performed using membranes of HEK293T without the 
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receptor being expressed.  Without receptor, BGDP formation in presence of 100 μM 
UK14,304 was 100 ± 3% of that without drug (n = 5), indicating no stimulation of 
BGDP formation over background.  Similar results were obtained in the presence of 
10 μM GTP.  In the second control, stimulation in the presence of 10 μM GTP was 
tested in membranes expressing the α2AAR-C351I fusion protein.  In these 
experiments, BGDP formation rate with drug was 97 ± 2% (n = 5) of that without 
drug, indicating no stimulation of high KM GTPase activity by the α2AAR agonist. 
This latter result also demonstrates the effectiveness of the unlabeled GTP in 
suppressing receptor-mediated GTPase activity. 
 
Assay Reproducibility  
The relative standard deviation (RSD) of the BGDP/IS ratio within a sample was 
<5% (for an average of 10 electropherograms), suggesting good reproducibility in the 
measurement of activity in one sample.  This reproducibility was similar for 
standards and is inherent in the CE-LIF measurement.  Total BGTPase activity 
measured in samples prepared for a given condition (e.g., drug concentration) from 
the same membrane preparation on different days had relative standard deviations 
<8% (n = 3 for each condition).  Specific activity had higher RSDs, especially at low 
drug concentrations (see Figure 2-2), as a direct result of the background subtraction. 
The average nonspecific or background GTPase activity that was subtracted was 80 ± 




 (n = 6) whereas the activity recorded for the 











.  Subtracting two similar numbers with small variability resulted 
in relatively larger errors for specific activity measurements. 
 
Assays with Wild-Type Gαo1 and RGS Protein  
Agonist-stimulated GTPase activity was also detected for membranes expressing 
α2AAR-wt Gαo1 fusion (Figure 2-3).  Basal levels of specific G protein GTPase were 




 (n = 10) for samples containing 58.6 fmol of 
fusion protein.  Addition of 10 μM UK14,304 resulted in a increase to 145% of basal 




, n = 9, p < 0.0025).  The extent of 
stimulation is less than the maximal agonist-stimulated increase detected in 
membranes containing an equivalent amount (58.6 fmol) of C351I fusion protein 









).  This result is consistent with less efficient stimulation of wt as 
compared to C351I fusion proteins for equivalent amounts of receptor as reported 





Figure 2-3. Agonist-stimulated specific GTPase activity can be modulated with 
RGS8.  Data shown are for membranes expressing the wt and mutant fusion protein.  
Stimulation in the presence of 10 μM UK14,304 and 10 μM UK14,304 + RGS8.  
Differences with ** are significant with p < 0.001 and with * are significant with p = 
0.0025.  Error bars are 1 standard error of the mean. 
 
RGS proteins modulate GPCR signaling by binding G proteins and accelerating 
the hydrolysis of bound GTP and inactivating the G protein.  Because of this effect, 
these proteins are an emerging drug target (e.g., RGS inhibitors are expected to 
greatly enhance the effect of a GPCR agonist)
50
.  To determine if we could detect 
modulation of the GPCR activity by RGS, we measured agonist-stimulated GTPase 
activity in the wt fusion membrane samples in the presence of RGS8.  As shown in 
Figure 2-3, agonist-stimulated GTPase activity was amplified to 210% of basal levels 




, n = 7) by the addition of GTPase-accelerating 
protein RGS8 to the sample.  For mutant G protein, even greater levels of 
stimulation were achieved (Figure 2-3).  The ability to separately detect the effect of 
RGS proteins highlights an important advantage of this in vitro approach over 
41 
cell-based assays (i.e., reagents or intracellular modulators can be added directly to 
solution to monitor their effect on the reaction), meaning that interactions downstream 
of the GPCR (such as the RGS−G protein interaction used here) can be monitored. 
Thus, the developed assay could also potentially be used to screen for RGS inhibitors, 
in addition to novel GPCR ligands. 
 
Direct Injection Assays  
The results from these experiments illustrate that the CE-LIF assay can be used to 
detect agonist-stimulated GTPase activity.  Significant improvements would be 
required for the assay to be considered suitable for high-throughput screening.  One 
area of improvement is assay reproducibility.  The reproducibility of assays used in 
high-throughput screening may be assessed using the Z‟-factor, which is calculated as 
Z‟ = 1.0 − (3.0 × (sneg + spos)/R) where sneg is the standard deviation of the response of 
a negative control (no drug), spos is the standard deviation of the response to a positive 
control (active drug), and R is the difference in signal between the mean of positive 
and negative controls
45, 121-124
.  The maximum Z‟ is 1.0, and Z‟ over 0.5 is considered 
necessary for high-throughput screens.  The assay described had a Z‟ = 0.4 
suggesting that improvements were needed to make this assay viable for 
high-throughput screens. 
We therefore investigated modifications of the assay aimed at improving 
reproducibility.  To improve the assay, we focused on eliminating the membrane 
filtration step because not only did it seem likely to be a source of error, but it also 
42 
made the assay more complex and slower.  To avoid the membrane filtration step, we 
directly injected without filtering using the flow-gated interface.  The resulting 
electropherograms were cluttered with spikes, apparently associated with injection of 
the membrane particles.  The nucleotide peaks could be resolved from the spikes 
using a modified electrophoresis buffer as shown in Figure 2-4.  These conditions 
resulted in loss of resolution of the BGTP and BDP isomers; however, the loss of 
resolution was considered inconsequential given the similar behavior of the isomers in 
the assay.  To better suppress background, we added 0.53 mM App(NH)p to the 
incubation media.  This reagent has been shown to help reduce the high KM GTPase 
activity
122
.  A dose−response curve using these modifications is shown in Figure 2-5. 
The data shown in Figure 2-5 illustrate the curves with and without the background 
subtraction.  Using this approach, the Z‟ factor was improved to 0.8.  Even without 
the background subtraction step, the Z‟ factor was 0.7.  Similar Z‟ factors were 
obtained when using the α2AAR-wt Gαo1 fusion.  We conclude that the use of direct 
injection simplified the assay, improved the reproducibility, eased the potential for 




















Figure 2-4. Electropherogram obtained using the direct injection assay 
conditions.  Sample shown was for basal conditions (i.e., without drug) following 






























Figure 2-5. Dose−response curve obtained using direct assay conditions.  
Both background subtracted (low KM GTPase) and raw data (total GTPase) activities 
are shown. Total GTPase was observed to increase 1.9-fold over basal levels when 0.1 
mM UK14,304 was present.  When the nonspecific, high KM GTPase activity was 




The success of the assay is perhaps surprising in view of previous work 
suggesting that the bulky BODIPY moiety reduces the affinity of guanosine 
nucleotide analogues GppNHp and GTPγS for membrane-bound G proteins 17- to 
55-fold and 1100- to 5600-fold respectively
125
.  These prior results led to the 
conclusion that BODIPY-labeled nucleotides would be unsuitable for fluorescence 
studies in native membranes.  The discrepancies between the two results may arise 
from the difference between the two techniques used.  We directly measured 
consumption of BGTP and formation of BGDP, whereas previous studies indirectly 
assessed fluorescent nucleotide binding by measuring how effectively their presence 
blocked the receptor-stimulated hydrolysis of [γ
32
P]GTP.  It is possible, for example, 
that unaccounted for hydrolysis of the BGTPγS
107
 and BGppNHp contributed to 
apparent lower affinities in these competition experiments. 
The results presented herein demonstrate the use of fluorescent GTP analogues to 
study receptor-mediated GTPase activity in cell membranes.  The method yielded 
expected responses in the presence of GPCR agonist and antagonist, with EC50s 
comparable to those obtained from traditional techniques using [γ
32
-P]GTP as 
substrate, without the drawbacks associated with radioactivity.  In the direct injection 
format, the assay also has potential to serve as the basis for high-throughput screening 
applications.  Use of the assay for high-throughput screens would require adaptation 
to array CE-LIF systems
16
 or microchip formats
35, 126
 that would offer parallel 
analysis and increased throughput.  Another area of exploration is how versatile the 
45 
approach would be for different G protein systems.  These data were obtained using 
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Introduction 
Determination of enzymes and their kinetics is important in biotechnology, 
biochemistry, clinical chemistry, and pharmaceutical development
127-129
.  
Increasingly, high-throughput characterization of enzymes is important.  This is 
especially true in drug discovery where chemical libraries are commonly screened for 
potential drugs that inhibit or activate enzymes that are therapeutic targets
127, 130
.  
Where feasible, enzyme activity is assessed using photometric or fluorometric 
methods to measure changes in substrate and product concentrations
131, 132
.  If it is 
not possible to distinguish substrate and product by those techniques, then other 
methods such as radiochemical assays or HPLC may be used
133
.  While these latter 
methods are acceptable in many cases, they are not well-suited for high-throughput 
applications.  
Capillary electrophoresis (CE) has emerged as a promising means to detect 
and monitor enzyme activity as an alternative to HPLC or radiochemistry
134-136
.  
Advantages of CE include low sample consumption, rapid analysis, high sensitivity, 
47 
and efficient separation of product from substrate for detection and quantification CE 
enzyme assays can take several forms based on how the enzyme and substrate are 
mixed including: 1) pre-column mixing where CE is used to analyze reaction mixtures; 
and 2) on-column mixing, also called enzyme-mediated microanalysis, where 
substrate and product are mixed electrophoretically within the capillary
128, 135, 136
.  
With pre-capillary mixing, it is possible to use rapid CE to continually monitor a 
reaction and determine enzyme kinetics
112
.     
The throughput of enzyme assay by CE can be increased by performing 
separations in parallel using capillary bundles
16, 58, 137-139
.  In most cases, capillaries 
used in array instruments are 40-80 cm long and have 50-100 μm i.d.  These 
capillary dimensions are suitable for high efficiency, but cannot deliver high-speed 
analysis
15
.  Slow separation compromises the improvement of throughput brought 
about by using large number of capillaries and precludes experiments aimed at 
monitoring reaction kinetics.   
A promising alternative to capillary-array devices is chip-based CE
140-144
.  
Separation channels a few centimeters long can be easily fabricated on a glass 
substrate allowing rapid separations.  Assays of a variety of enzymes including 
β-galactosidase
145




 have been 
demonstrated on single-channel chips.  Increasing the number of channels can be 
achieved for significantly improved throughput.  Chips with as many as 384 
channels have been demonstrated for genetic analysis
148
; however, relatively few 
applications have been reported demonstrating enzyme assays on multi-channel CE 
48 
devices.  Increased throughput for electrophoretic enzyme assay has been 
demonstrated on a 4-channel, optically-gated CE device
35
.  In that study, 
β-galactosidase was screened against a few inhibitors demonstrating modest 
throughput.  A commercial system (Caliper HTS) is available with 4 parallel 
channels (now also available with 12 channels) to generate throughput of 384 samples 
in 80 min for kinase assays
36, 37
.  This sophisticated device also incorporates 
automated sampling from multi-well plates and automated chip conditioning.  In this 
work we explore the use of 16- and 36-channel chips that are suitable both for 
monitoring reactions on the second time scale to determine kinetics and for analyzing 
quenched reactions.   
We use an assay of G protein GTPase activity as a model because of its 
significance in intracellular signaling
42, 149
.  When a G protein-coupled receptor 
(GPCR) is activated, it stimulates exchange of GDP for GTP in the Gα subunit of the 
heterotrimeric G protein associated with the GPCR.  The Gα-GTP complex is active, 
sending signals to downstream effectors such as adenylyl cyclase.  Hydrolysis of 
GTP to GDP by the G protein terminates the signal.  It has been shown that GTPase 
activity can be accelerated by Regulators of G protein Signaling (RGS) proteins 
which bind the G protein
49, 50, 150
.  G protein hydrolysis activity and its regulation by 





, and drug addiction
153
 suggesting that agents 
that increase RGS activity may be useful in treating these conditions.  Substances 




Currently available assays for GTPase activity and its modulation by RGS are not 
ideal.  The most common GTPase assay uses [γ-
32
P]GTP as G protein substrate
154
.  
A fluorescence assay based on changes of G protein intrinsic fluorescence during 
hydrolysis was also demonstrated
52
.  Binding of G protein and RGS protein has been 
detected by flow cytometry and used in screening for potential RGS inhibitors
155
.  
These methods are either inconvenient for high-throughput or do not report on actual 
hydrolysis activity.  Recently we demonstrated that GTPase activity and modulation 
by RGS could be detected by using BODIPY
®
 FL GTP (BGTP) as substrate and rapid 
CE to detection conversion to the product BODIPY
®
 FL GDP (BGDP)
112
.     
In this work, we used multi-channel electrophoresis chips to monitor GTPase 
activity in real-time for kinetics determinations.  Potential applications include rapid 
determination of kinetics, determination of enzyme concentrations, and optimization 
of reaction conditions.   In addition, we mimicked drug screening against G protein 
and RGS protein and characterized dose-response curves. 
 
Experimental Section 
Materials   
BGTP and BGDP were obtained from Molecular Probes, Inc. (Eugene, OR).  
Gαo and RGS8 were expressed and purified as described previously and stored at 
-80  until used
112
.  The peptide Ac-Val-Lys-c(Et)[Cys-Thr-Gly-Ile-Cys]-Glu-NH2 
(YJ34), where c(Et) designates cyclization via an ethylene dithioether linking the Cys 
side chains, was synthesized and purified as previously described
156
, dissolved in 
50 
DMSO and stored as 2 mM aliquots at -20 °C.  Methyl 
N-[(4-chlorophenyl)sulfonyl]-4-nitrobenzenesulfinimidoate (CCG-4986) was from 
the screening compound library from the Chembridge screening collection 
(hit2lead.com)
155
.  All other chemicals were purchased from Sigma.  All buffers 
were made using Milli-Q (Millipore, Bedford, MA) 18-MΩ deionized water and 
filtered using 0.2-μm SFCA membrane filters (Nalgene Labware, Rochester, NY).  
All BGTP hydrolysis experiments were performed with Tris-Glycine buffer 
supplemented with 1 mM EDTA and 10 mM MgCl2 (TGEM buffer) as the solvent 
except for those studying the effect of Mg
2+
 on Gαo GTPase activity.  Electrophoresis 
buffer was Tris-Glycine buffer (pH 8.3) supplemented with 8 mM MgSO4.  
 
Microfluidic Chip Fabrication   
Microfluidic networks consisting of either 16 or 36 separation channels were 
fabricated on a 76 mm × 76 mm borofloat glass substrate according to a previously 
described procedure
157
.  Briefly, 0.7 mm thick borofloat glass photomask blanks 
pre-coated with a 530-nm layer of AZ1518 positive photoresist on top of another 
120-nm layer of chrome were purchased from Telic Co. (Santa Monica, CA).  A 
custom-made photomask (Fineline Imaging, Colorado Springs, CO) patterned with 
the microfluidic network (Figure 3-1 (a) and (b)) was used to transfer the network 
design onto the photomask blanks by exposing for 4 s at 26 W cm
-2
.  The exposed 
photomask blanks were developed in AZ915 MIF developer (Clariant Corp., 
Sommerville, NJ) and then treated with CEP-200 chrome etchant (Microchrome 
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Technologies, Inc., San Jose, CA).  12 μm deep channels were then formed by 
etching the exposed glass in 14:20:66 (v/v/v) HNO3/HF/H2O for 20 min.  360 μm 
diameter access holes were drilled onto the etched plate with diamond-tipped drill bits 
(Kyocera, Ervine, CA).  Both the etched and another blank substrate were 
thoroughly cleaned in Piranha solution (3:1 v/v H2SO4/H2O2) for 20 min and then 
with RCA solution (5:1:1 v/v/v H2O/NH4OH/H2O2) for 40 min at 60 .  The 
cleaned substrates were pressed together when wet and bonded at 610 °C for 8 h in a 
Neytech Centurian Qex furnace (Pacific Combustion, Los Angeles, CA).  Sample 
and buffer reservoirs were attached to the bonded chip using epoxy (Epo-Tech., 
Bellerica, MA).  Figure 3-1 (c) shows the completed 36-channel chip.  
 
Mircrofluidic Chip Operation   
Before use, chips were conditioned with 0.1 M NaOH in 50:50 (v/v) 
H2O/methanol by electrophoretically perfusing the solution through all channels for 
30 min.  This treatment was followed by conditioning channels with deionized water 
and electrophoresis buffer for 5 min each.  To prepare the chip for CE separation, 
samples were loaded onto sample reservoirs which were grounded using a platinum 
electrode array fabricated in-house.  As shown in Figure 3-1 (e), samples were 
driven towards the injection cross channel by voltage 1 (-4 kV and -2.5 kV for 16 and 
36 channel designs respectively) at the chip center.  Sample loading onto the 
separation channel at the injection cross was controlled by voltage 2 and the relay 
(Kilovac, Santa Barbara, CA) connected at the waste 1 and gate reservoirs 
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respectively.  (These reservoirs were common to all electrophoresis units as shown 
in 3-1 (b)).  With the relay closed sample was shunted to waste 1 while opening the 
relay for 0.5 to 1.0 s allowed a plug of sample to be injected onto the separation 
channel.  All voltages were applied with a Spellman High Voltage Electronics 
CZE1000R power supply (Happauge, NY).  Applied voltage and frequency of 
injection were controlled by a personal computer equipped with a multi-function 
board (AT-MIIO-16, National Instruments, Austin, TX) using software written 
in-house. 
 
Fluorescence Detection and Data Analysis   
Excitation light from a 300 W Xe arc lamp (LB-LS/30, Sutter Instrument 
Company, Novato, CA) was filtered through a FITC filter cube (Semrock, Rochester, 
NY) before it was focused onto the chip detection region at the center of the chip 
(Figure 3-1 (d)) with an objective lens (Olympus America Inc., Melville, NY).  
Emission light was collimated with the same objective and detected using an 
electron-multiplying CCD camera (C9100-13, Hamamatsu Photonic Systems, 
Bridgewater, NJ).  Time-lapse fluorescence images of the detection region were 
collected using an inverted epi-fluorescence microscope (IX71, Olympus America, 
Inc., Melville, NY) at ~15 Hz and analyzed with Slidebook software (Intelligent 
Imaging Innovations, Inc., Denver, CO).  Electropherograms from individual 
channels were reconstructed from the images before they were analyzed using 
software written in-house
158
.  To test this system for cross-talk between channels, 
53 
solutions without fluorophore were injected into channels parallel to those with 
fluorophore.  No peaks were detected in the blank channels.  In addition, no signal 
was detected when imaging the area between channels when all channels had 
fluorophore pumped through them.  From these results we concluded that no 






Figure 3-1. Microfluidic devices used for parallel electrophoretic enzyme assays.  
(a). Design of microfluidic network containing 16 parallel separation channels. 
Dimensions of each section were as follows: 7 mm from sample access hole to 
injection cross; 27 mm for separation channel (from injection cross to center where all 
separation channels converge); 8 and 13 mm for two other channels connecting the 
injection cross; 35 mm long and 6 mm wide at the widest point for the common waste 
channel.  (b) Design of 36-channel network. Dimensions were similar to the 
16-channel chip except the common waste channel was 40 mm long and 13 mm wide 
at the widest point. (c) Photograph of finished 36-channel chip.  1 cm long glass 
tubes of volume of 50 μL each were used for individual sample reservoirs.  Two 
groups of access holes were separately connected to gate reservoir and waste reservoir 
which were formed by using three glass rings.  Common waste channel led to 
another cathode reservoir to which –HV was applied. (d). Bright-field image of the 
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detection area on the 36-channel chip. (e) Repetitive units of microfluidic network.  
Electrokinetic injection procedure is described in experimental section. 
 
G protein assay and drug screening   
Assays were done in a real-time monitoring format on the 16-channel chip.  
Hydrolysis was initiated by mixing G protein and BGTP in reaction buffer and then 
loading 50 L of the sample into sample reservoirs on the chip.  Periodic injections 
were then made to track the evolution of BGDP peak.  The initial portion of BGDP 
peak growth was fitted to a linear equation and the resulting slope converted to 
hydrolysis rate using a previously acquired calibration curve.  Derived hydrolysis 
rates were used as indications of G protein enzymatic activities.  On the 36-channel 
chip, all assays were performed on quenched reactions.  G protein, BGTP and other 
modulators as indicated were incubated in the TGEM buffer at room temperature for 
specific period before reactions were quenched by adding excess GTPγS.  The 
quenched reactions were stored on ice prior to loading on chip for analysis.  The 
final BGDP concentrations were derived and quantified from the acquired 
electropherograms and calibration curves.  BGDP formation was calculated by 
subtracting out the initial BGDP residue existing in the BGTP sample.  The 
calculated BGTP turnover rates were used to determine the stimulatory or inhibitory 
effects of test substances. 
 
Results and Discussion 
Chip Performance   
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Electrophoretic assay of GTPase activity requires separation and quantification of 
the G protein substrate BGTP, the product BGDP, and the internal standard rhodamine 
110 (R110).  To determine kinetics by monitoring the enzyme reaction, it is 
necessary to perform serial injections from a given sample at a rate sufficient to 
achieve adequate temporal resolution.  Separation time also affects the ability to 
perform high throughput assays.  To implement parallel enzyme assays on chip, 
reliable and reproducible channel performance, including reproducible migration 
times across channels, is required.  We therefore tested the 16- and 36-channel 
devices for their suitability for serial separation of substrate, product, and internal 
standards. 
Typical serial electropherograms on a 16-channel chip are shown in Figure 3-2.  
As shown, the substrate, product, and internal standard were well-resolved in 18 s and 
injections could be reliably performed serially across all channels.  The separation 
time is limited by the electric field applied to the separation channel.  In the 
16-channel design, electrical resistance of separation channel is about 250-fold that of 
the common waste channel.  The total resistance of 16 parallel separation channels is 
about 15-fold that of the common channel.  Therefore, with -4 kV applied to the 
cathode reservoir an electric field of -1.1 kV/cm was developed in the separation 
channels.  In the 36-channel design, electrical resistance of a single separation 
channel is about 470-fold that of the common channel.  So the total resistance of 36 
parallel separation channels is about 13-fold higher than that of the common channel.  
In similar experiments with 36-channel chips, -2.5 kV was applied to the cathode 
57 
resulting in – 0.68 kV/cm electrical field.  As a result, the separation of R110, BGDP 
and BGTP took longer, about 30 s.  At these voltages Joule heating, evidenced by 
non-linear Ohm plots, was not observed.  Rather, voltages applied in both cases were 
limited by the maximal current allowed by the high-voltage power supply.  Should 
higher current power supplies be available a higher separation voltage could be 
applied to attain even faster and higher resolution separation.   
 
 

















Figure 3-2. Typical serial electropherograms acquired in parallel from a 16 
channel-chip.  Solution containing 26.2 nM rhodamine 110 (peak 1), 1.0 μM BGTP 
(peak 3) and trace amount of BGDP (peak 2) was serially injected 4 times onto each 
channel at 20 s intervals.  
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The reproducibility of migration times for both the 16- and 36-channel chips 
was excellent with RSDs of 1.5% (n = 6) and 2.5% (n = 6) respectively.  Good 
reproducibility allowed for controlling injection on all channels using a single 
high-voltage relay because the injections could be performed simultaneously.  This 
simplified instrumentation as well as computer control of the relay.     
Within a single channel, RSDs of peak area of R110 and BGDP were about 
1.5% and 2.0% respectively, and that of the peak area ratio BGDP/R110 was around 
3%.  Absolute peak areas across all channels were not reproducible enough to 
achieve quantification (relative standard deviation could be as high as 33%).  
Therefore relative peak area of BGDP to R110 was always used for quantification.  
In the 16-channel design, the relative standard deviation of BGDP peak area 
normalized to internal standard R110 was around 5% across all channels.  However, 
in the 36-channel design, the RSD was increased 11%.  This RSD is acceptable for 
quantification in some cases, but the best quantitative results were obtained by 
calibrating each channel individually.   
We next compared calibration curves across different channels by plotting 
BGDP/R110 peak area ratios as a function of BGDP concentration from 100 to 800 
nM.  Linear response was found for all channels with variation of 5.1% in slope for 
both the 16- and 36-channel designs indicating good channel-to-channel homogeneity.  
Therefore all channels had similar sensitivity and detection limit of GTPase activity.  
It is desirable that chips maintain their performance as long as possible.  The 
most common reason for chip failure was particle accumulation, especially around the 
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common outlet.  In preliminary experiments, we found that a wide common waste 
channel was essential in preventing particulates from accumulating at the outlets of 
separation channels.  This is probably because the wide channel helps decrease 
pressure build-up at the center of the chip and facilitates particles and fluid passing 
through the waste channel.  With the wide channel, small particles could be observed 
passing through the common channel and clogging rarely happened in the separation 
process.  Precipitate that did build up during chip storage could be easily removed by 
perfusing diluted nitric acid, water, and then NaOH through channels by vacuum.  
By using these procedures a chip could be used daily for at least 2 weeks (~400 
electrophoresis injections per channel per week) without significant loss of 
performance.  As the chip was used, the differences in migration times were large 
enough to make parallel analysis difficult.  Even after this time, however, 
intrachannel reproducibility for migration time and peak areas was sufficient for 
quantitative analysis.  
 
Parallel Kinetic Enzyme Assays on Chip   
We next explored the possibility of using multiplexed channel chip to monitor 
GTPase hydrolysis kinetics of multiple samples simultaneously.  For these kinetics 
experiments, the 16-channel chip was used because of the better temporal resolution.  
In initial experiments, BGTP hydrolysis rates at different concentrations of G protein 
were examined.  G protein at 8 different concentrations from 10 to 125 nM was 
mixed with a fixed concentration of substrate BGTP.  Immediately after mixing the 
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mixtures were loaded into separate sample chambers on the chip (each concentration 
of G protein was loaded onto and analyzed by two different channels) and monitored 
by serial electropherograms acquired at 20 s intervals.  The resulting hydrolysis rates 
from those two channels were averaged to generate calibration curves for G protein 
concentration.  These curves could be fit by linear regression (slope = 0.0087  
0.0008 nM BGDP formed per nM G protein/s, r
2
 = 0.83 for n=4 calibrations).  The 
linear fit could be improved by using only the G protein concentrations from 10 to 60 
nM (r
2
 = 0.94) due to nonlinearity and lower reproducibility at high G protein 
concentrations.  These effects at higher G protein concentrations occurred because it 
took about 5 min to load the samples into the chip and during this time rapid 
hydrolysis that occurred at higher protein concentrations consumed sufficient BGTP 
to affect the rate measurement.  Variation in time of sample loading would directly 
lead to variation in measured rates.  Automated loading or on-chip mixing would 
alleviate this problem.  Channel-to-channel reproducibility at low G protein 
concentrations was generally good, below 15%.  Under conditions used in the 
experiments, the limit of detection (LOD) for G protein by its enzymatic activity was 
10 nM.  This detection limit could easily be improved by increasing the incubation 
time using off-line assay.  
For characterizing enzymes, it is often necessary to vary buffer composition to 
identify how different factors affect enzyme behavior and to optimize conditions.  
For example, G protein hydrolysis is dependent upon Mg
2+ 
which is required for 
BGTP to effectively bind to G protein.  Optimizing conditions can be a slow process 
61 
if performed serially.  To demonstrate rapid reaction optimization using the 
16-channel chip, we varied the Mg
2+
 concentration and monitored hydrolysis kinetics.  
By monitoring BGTP hydrolysis by G protein at 8 concentrations of Mg
2+
 in duplicate 
on the 16-channnel chip, the optimization could be accomplished in a single 
experiment (Figure 3-3).  The results showing a linear increase up to 2 mM Mg
2+
 are 
in good agreement with previous studies
112
. 
The multi-channel chip also allows kinetic parameters of enzymes to be 
rapidly determined.  For example, measuring enzymatic activity across a range of 
substrate concentration is used to determine KM.  This process can be greatly 
shortened by running assays on the 16-channel chip.  In our experiment, BGTP of 
concentrations ranging from 50 nM to 2.5 μM was mixed with 42 nM G protein and 
loaded onto the 16-channel chip.  The hydrolysis rate at each BGTP concentration 
was monitored in two separate channels.  As shown in figure 3-4, BGTP turnover 
rates can be fitted to the Michaelis-Menton equation.  KM and kcat calculated by 
curve fitting were 305 ± 85 nM and 0.015 ± 0.001 sec
-1 
respectively.  These results 
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Figure 3-3. Optimizing enzyme assay conditions.  (a) BGDP peak heights 
recorded by serial electrophoresis from 16-channels when BGTP was hydrolyzed by 
Gαo at various Mg
2+ 
concentrations.  Each sample reservoir was filled with a solution 
of 83.3 nM Gαo , 1 μM BGTP, and 21.8 nM R110 in TGE buffer spiked with Mg
2+ 
concentrations as shown.  Each Mg
2+
 concentration was used in two separate 
channels.  BGDP formation was monitored and BGDP/R110 ratios were used to 
indicate the real-time concentrations of BGDP in the reaction mixtures. (b) Plot 
showing Gαo hydrolytic activities at different Mg
2+ 
concentrations. Hydrolysis rates 
indicated by BGDP formation (nM/sec) were derived from linear fitting of Figure 4 

































Figure 3-4. Determination of Enzyme Kinetics.  20.8 nM Gαo was incubated with 
0.05, 0.1, 0.2, 0.3, 0.5, 1.0, 2.0, and 2.5 μM BGTP respectively in TGEM buffer at 
room temperature.  Hydrolysis rates expressed in turnover number were calculated 
by real-time monitoring and plotted against BGTP concentrations.  Data were fit to 
the Michaelis-Menton function. 
 
 
Although enzyme kinetics can be measured by a variety of analytical techniques, 
the results shown here illustrate a unique potential for rapid separations in parallel 
channel electrophoresis.  Optical methods in principle could be operated in parallel, 
but they require changes in optical properties upon conversion from substrate to 
product which is not always the case, as is true here for GTP with the BODIPY label 
on the sugar ring.  Radiochemical methods require hazardous substances and 
frequent multiple washing and rinsing steps.  Slower parallel CE methods are not 
well-suited for on-line kinetics measurements.  Thus, the combination of rapid 
measurement in parallel with electrophoretic separation allows kinetics to be 
measured in parallel even for enzymes where the substrate and product are 
indistinguishable by optical methods.   
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Parallel Analysis of Quenched Reaction Mixtures: Drug Screening and Dose 
Response Curves   
In addition to the multi-point kinetic data, it is also frequently of interest to 
measure the extent of reaction at a fixed time point.  For example, dose response 
curves for compounds that affect enzyme activity are typically measured at fixed 
times.  Similarly, in combinatorial screening for enzymatic activators or inhibitors, 
the extent of reaction at a single time point is often measured.  We therefore 
examined the possibility of performing such measurements using the multiplexed chip.  
In this experiment, serial analysis was less important than parallel measurements so 
the 36-channel chip was used.  
Because RGS has become an interesting drug target, we tested the possibility 
of screening against RGS protein effects on GTPase activity.  The principle of the 
assay is illustrated in Fig. 3-5.  G protein was mixed with substrate for a fixed period 
and the hydrolysis reaction was then quenched by addition of an excess of the 
non-hydrolyzable GTP analog GTPγS (see Experimental section for details).  As 
shown in Fig. 3-5, the extent of hydrolysis reaction is increased by the presence of 
RGS protein in the reaction mixture.  Inhibition of RGS activity results in less net 
hydrolysis.  Therefore, comparison of BGDP formation with and without test 
compound in the presence of RGS allowed detection of inhibitors.  The steady state 
assay used here is made possible by the rapid dissociation of BGDP from G protein.  
RGS assays normally require a single turnover format, which is requires more 
sophisticated mixing because the RGS effect is masked by slow dissociation of GDP 
65 
from the G protein. 
 
 
Figure 3-5. Electrophoretic assay for RGS GTPase accelerating activity and its 
inhibition.  (left) Basal hydrolysis by Gα alone results in formation of BGDP from 
BGTP; (middle) RGS protein accelerates the GTPase activity of Gα resulting in a 
larger BGDP peak formation; (right) addition of an inhibitor interferes with RGS and 
Gα interaction and thus diminishes the acceleratory effect of RGS protein resulting in 
a smaller BGDP peak in the electropherogram.  All solutions were incubated for 20 
min and then quenched with 10 µM GTPγS before electrophoretic analysis.  
 
 
For the screen we tested the effect of 11 compounds.  YJ34 had previously been 
shown to interfere with G protein-RGS8 binding and would therefore be expected to 
inhibit BGTP hydrolysis
161
.  CCG-4986 was reported to interfere with G 
protein-RGS4 binding but not G protein-RGS8 binding and was expected to not have 
an effect
155
.  The other 9 compounds were known drugs but not expected to have any 
activity on this system.  Each reaction mixture containing one drug was analyzed in 
triplicate using three separate channels.  The results are summarized in Figure 3-6.  
As shown, the expected inhibitory effect of YJ34 was detected and the 9 negative 
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controls gave similar responses to each other.  Interestingly, CCG-4986 showed an 
inhibitory effect.  This could be due to several possibilities including: 1) inhibition of 
hydrolysis activity independent of inhibition of binding, which is one of the reasons 
for using activity instead of binding assays or 2) an artifact of using BGTP instead of 
GTP in the assay.  While further work would be required to resolve this issue, the 
data overall illustrate the potential for screening with the chip-based system.  We 
used Z‟ value to evaluate the reproducibility of the assay.  The Z‟ is by definition = 
1.0 - (3.0 × (sneg + spos) / R) where sneg and spos are the standard deviation of the signal 
of negative and positive controls respectively, and R is the difference between the 
mean of positive and negative controls
162
.  We determined a Z‟ = 0.7 for the assay 
which is well above the 0.5 considered necessary for high-throughput screening.  
Also, the assay only required 30 s (the separation time) for 11 compounds to be 
analyzed (in addition to one control sample) in triplicate corresponding to a 
throughput of 1,440 samples per hour.  If only single samples were analyzed the 
throughput could be 4,320 samples per hour.  Naturally, achieving throughput this 
high would require a means of introducing new samples to the chip rapidly and 
automated sample preparation procedures. 
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Figure 3-6. GTPase accelerating activity of RGS8 in the presence of test 
compounds.  1 μM BGTP was incubated with 20 nM Gαo and 321 nM RGS8 in the 
presence of 11 different compounds.  BGDP formation rates were used indicate 




We also tested the ability to quantitatively determine dose-response curves 
across channels with a single experiment.  Nine concentrations of Gαo inhibitor 
GTPγS and activator RGS8 separately were included in the reaction mixtures 
containing G protein and BGTP.  After incubation of 30 and 15 min respectively, 
reactions were quenched with GTPγS and put on ice before analysis.  Each reaction 
mixture was analyzed in two separate channels and BGDP formation was quantified 
(Figure 3-7).  GTPγS showed IC50 of 18.8 nM and a maximal inhibition of 97.7% of 
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basal GTPase activity.   
 























Figure 3-7. Dose response curve for GTPγS inhibiting Gαo GTPase activity.  Nine 
concentrations of GTPγS were tested for the effect on basal BGTP hydrolysis rate.  
Reaction mixture containing each concentration of GTPγS was analyzed in 2 separate 
channels.  The calculated IC50 value was 18.8 ± 8 nM.  At maximal inhibition 




The microfabricated channel-array electrophoresis device described here is 
suitable for parallel enzyme assays.  The combination of fast separations and parallel 
operation yields a versatile platform for determining kinetics, enzyme concentrations, 
optimizing reactions, screening inhibitors, and determining dose response curves.  
Although the system has the potential for high throughput screening assays, the 
development of improved sample introduction will be required for this system to be 
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used for such applications.  The assay for RGS-G proteins appears to be sufficiently 
sensitive for drug screening.   
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CHAPTER 4 
PARALLEL ELECTROPHORETIC ANALYSIS OF SEGMENTED SAMPLES 




Capillary electrophoresis (CE)-based micro-total analysis system (µTAS) has 
greatly evolved since the first demonstration of CE separation on microfluidic devices 
in 1992
21
.  CE is by far the dominant separation technique for on-chip analysis not 
only because it is the easiest to impletment but it also enables fast analysis, low 
sample consumption and requires no external pumping.  A broad spectrum of 
analytes including DNAs, proteins and small molecules have been separated by CE on 
chip
22, 23
.  Until recently, research interest in this area has mostly been focused on 
improving separation efficiency and integrating other laboratory functionalities such 
as mixing and reaction.  Achieving high throughput using such electrophoresis 
devices has also gained attention.  Performing parallel CE separation on devices 
consisting of multiple separation channels is the most prominent approach to this end.  
Initially parallel CE separation was demonstrated for DNA sequencing and 
genotyping by Mathies‟ group
38
.  Up to 384 separation lanes have been 
microfabricated on a single device for high-throughput genetic analysis
40
.  Parallel 
71 
CE separation has also found applications in immunoassays
163, 164
 and enzyme 
assays
30, 35-37
.  For example, we previously developed a microfluidic device which 
consisted of up to 36 parallel electrophoretic channels.  With fast separation in each 
channel, 36 enzyme assay mixtures could be analyzed in 30 seconds
30
.  However, in 
most of the above works, samples were loaded into the reservoirs manually.  When a 
different set of samples were to be analyzed, it required that reservoirs be emptied, 
cleaned, and re-loaded.  This time-consuming step undermined the high throughput 
achieved by parallel separation.  Therefore further improvement in sample handling 
is required to achieve real high throughput and enable applications such as 
high-throughput screening (HTS).  Even though robotic systems have been built for 
automated sample loading and changing, the overall throughput still fell short of HTS 
requirements.   
 Effort has been devoted to devising so-called world-to-chip interfaces which 
would allow delivering discrete samples to the inlet of the CE channels for continuous 
analysis
165
.  Most of the designs utilized a sample introduction channel which had a 
much lower flow resistance than the separation channels.  Samples were perfused 
through this channel without causing significant pressure-driven flow in the rest of the 
chip.  A fraction of the sample flow was pulled by electroosmotic flow into the 
separation channel for injection.  To change samples, the previous sample was 
completely flushed out by the next sample before analysis so that low 
cross-contamination was possible.  An alternative to such flow-through sample 
reservoir was shown by He et al. where the sampling tip of the CE device was 
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inserted alternatively into samples and electrophoresis buffer stored in microvials 
fixed on a computer controlled autosampler platform
166
.  A similar but simpler 
sampling method that allowed direct CE injection was also reported
167
.  All these 
sample introduction schemes facilitated sample changing and increased analysis 
throughput; however, they did not address the issue as to how to transfer samples to 
chip.  Pipetting individual samples to the chip inlet was unavoidable.  Other 
disadvantages of these approaches included low sample utilization rate, complicated 
power control and external moving parts.   For example, tens of microliters of 
sample was required to flush out previous sample and fill the sample introduction 
channel while only nanoliters of sample was injected
165
.  Therefore more than 99% 
of the sample was wasted.  The moving stage for sample changing in another case 
added complexity to the instrumentation and compromised the benefits of 
microfluidic devices
166
.  An alternative sample introduction method to pipetting is 
transporting and feeding serial samples entrained in a multiphase flow to the analyzer.  
These so called continuous flow analysis techniques have been around for decades but 
until recently have not migrated to the microfluidic regime
168, 169
.  It has been shown 
that sample droplets or plugs on the nanoliter scale separated by an immiscible phase 
(such as gas or fluorinated oil) can be transported in an automatic fashion without 
significant cross contamination.  Various pre-analysis sample processing methods 






 have also been 
demonstrated.  However, methods for chemically analyzing segmented sample 
droplets have been largely limited to spectroscopic techniques such as absorbance and 
73 
fluorescence.  Only recently analyzing segmented flow using information-rich 
methods such as CE
85, 86
 and mass spectrometry (MS)
87, 172
 was demonstrated.  
Roman et al developed a microfluidic device for sampling and electrophretically 
analyzing aqueous samples segmented in an immiscible oil phase.  However 
manually aligning two microfluidic networks of different depths was required for the 
chip fabrication, which made it difficult to construct more than one of such unit on a 
single device.  Here we described a novel microfabricated interface to microchip CE 
for extracting and injecting samples from segmented flow.  This way multiple 
interfaces could be fabricated on a single chip allowing parallel analysis of segmented 
sample streams.  The entire analysis was automated with no need for power 
manipulation.  We envision the utilization of this device for automated 
high-throughput analysis such as HTS for drug discovery. 
 
Experimental Section 
Materials   
BODIPY
®
 FL GTP (BGTP) and BODIPY
®
 FL GDP (BGDP) were obtained from 
Molecular Probes, Inc. (Eugene, OR).  Gαo was expressed and purified as described 
previously and stored at -80  until used
30
.  All other chemicals were purchased 
from Sigma.  All buffers were made using Milli-Q (Millipore, Bedford, MA) 18-MΩ 
deionized water and filtered using 0.2-μm SFCA membrane filters (Nalgene Labware, 
Rochester, NY).  
BGTP hydrolysis experiment was performed in Tris-Glycine buffer 
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(containing 25 mM Tris and 192 mM glycine, pH 8.3) supplemented with 1 mM 
EDTA and 10 mM MgCl2 (TGEM buffer).  Electrophoresis buffer was Tris-Glycine 
buffer supplemented with 5 mM MgSO4 (TGM buffer).  
 
Microfluidic Chip Fabrication   
Microfluidic channels of two different depths were fabricated on two separate 76 
mm × 76 mm borosilicate (D263) glass substrate according to standard 
photolithographic procedure.  Briefly, 0.5 mm thick borosilicate glass pre-coated 
with a 530-nm layer of AZ1518 positive photoresist on top of another 120-nm layer of 
chrome were purchased from Telic Co. (Santa Monica, CA).  A custom-made 
photomask (Fineline Imaging, Colorado Springs, CO) patterned with the microfluidic 
network (Figure 4-1 (a) and (b)) was used to transfer the network design onto the 
photomask blanks by exposing for 6 s at 26 W cm
-2
.  The exposed photomask blanks 
were developed in AZ915 MIF developer (Clariant Corp., Summerville, NJ) and then 
treated with CEP-200 chrome etchant (Microchrome Technologies, Inc., San Jose, 
CA).  80 μm deep channels were then formed on one glass by etching the exposed 
glass in 50:50 (v:v) HCl/HF for 5 min and 45 sec.  360 μm diameter access holes 
were drilled onto this etched plate with diamond-tipped drill bits (Kyocera, Ervine, 
CA).  18 μm deep separation channels were created on another glass by etching in 
the same solution for 100 sec.  Both glass substrates were thoroughly cleaned in 
Piranha solution (3:1 v:v H2SO4/H2O2) for 30 min and then 60 °C in RCA solution 
(5:1:1 v/v/v H2O/NH4OH/H2O2) for 40 min.  The cleaned substrates were pressed 
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together when wet and bonded at 606 °C for 8 h in a Neytech Centurian Qex furnace 
(Pacific Combustion, Los Angeles, CA).  Nanoport
®
 microfluidic reservoirs 
(Upchurch Scientific, Oak Harbor, WA) were attached to the bonded chip over the 
access holes after bonding.  Additional 360 μm access holes were drilled from the 
side of the chip using flat-tipped drill bits from Kyocera so that they connect with the 
segmented-flow channels.  Water was perfused through the channels during drilling 
to prevent debris from clogging the channels.  The chip was thoroughly sonicated 
after drilling to clean out all remaining debris.  360 μm o.d. / 150 μm i.d. fused-silica 
capillaries (pre-treated with octadecyltrichlorosilane (OTCS) to make inner wall 
hydrophobic) were inserted into the access holes and glued in place using fast setting 
epoxy (Royal Adhesives & Sealants, Belleville, NJ) as the inlet of segmented flow.  




Figure 4-1. Design of a microfluidic device for parallel segmented flow analysis.  
(a) Three parallel designs of an interface for extracting aqueous sample droplets form 
the segmented flow.  Black dots will become access holes during fabrication.  
Positions 1-3 are buffer flow wastes and will be grounded.  Position 4 is common 
waste and will be biased to a negative high voltage; (b) Three parallel separation 
channels (labeled  1'-3').  The channels have a length of 3.4 cm and they converge 
at the center and connect with a common waste channel (wc); (c) blow up of circled 
region of one of the interfaces in (a).  a and b are 150 µm and 320 µm respectively; 
(d) blow up of the center of design (b).  Three separation channels are 5 µm wide by 
design and the wc is 120 µm wide.  
 


































Figure 4-2. Specifications of the finished chip. (a). A picture of the completed 
device.  Segmented flow enters the chip via the capillary labeled sample inlet.  
Buffer flow enters via buffer inlet using a nanoport connection unit.  Buffer waste is 
grounded and a negative separation voltage is applied to common waste; (b). A 
close-up look of the extraction interface.  The sample inlet capillary forms a dead 
volume-free connection with the microfluidic channel.  The end of the capillary is 
only 300 µm from where two channels connect.  Separation channel connects to the 
buffer channel at 300 µm downstream of the interface; (c) Cross section of the 
interface (not drawn to scale).  Both channels are 80 µm deep while the gap between 
them is only 5-10 µm deep; (d) Channel modification procedure.  The clear part 
shows the OTCS hexadecane solution flow profile (at 10 µL/min) while the dark part 




Channel Wall Modification   
In order to achieve phase separation for extracting aqueous droplets from the 
segmented flow, the microfluidic channels were selectively modified and made 
hydrophobic with OTCS
86, 173
.  The chip was kept dry in a desiccator until channel 
wall derivatization.  As shown in figure 4-2 (d), 0.5% OTCS solution in anhydrous 
hexadecane was flown through the segmented flow channel at 10 µL/min.  
Hexadecane was flown at the indicated directions at 2 µL/min.  A Valco 6 port valve 
(VICI Valco Instruments Co. Inc., Houston, TX) was used for switching the flow 
through the segmented flow channel between OTCS solution and hexadecane without 
interrupting the flow profile.  Stable flow was maintained for 4 min and bubbles 
flushed out before the flow was switched from hexadecane to OTCS solution for 7 
min.  The flow was switched back to hexadecane for another 14 min in order to flush 
out all residual OTCS.  After derivatization, all channels were flushed three times 
with 200 µL anhydrous hexane and then thoroughly dried under vacuum. 
  
Sample Preparation   
GTPase assay for G protein α unit (Gαo) was performed according to conditions 
reported before with some minor modifications
30
.  The hydrolysis was initiated by 
mixing 2 µM BGTP with 100 nM Gαo in the TGEM buffer and the mixture was 
incubated at room temperature for some amount of time before it was quenched by 
adding 20 µM GTP.  To generate cartridges containing nanoliter sample droplets, a 




.  In brief, 60 µL of deionized water was placed in all the wells of 
the 96-well plate before the whole plate was sprayed with MS-122DF PTFE release 
agent (Miller-Stephenson Chemical Co. Inc., Danbury, CT).  The water was then 
decanted and the plate dried before use.  60 µL of the quenched reaction mixtures 
were then placed in the plate and covered with an immiscible phase consisting of 
Fluorinert
®
 FC-40 (Sigma) supplemented with 1% perfluoro-1-octanol.  The 
modified plate surface kept the oil phase stable and on top of the aqueous samples 
even though it had a higher density.  A Teflon tube of 150 µm i.d. and 360 µm o.d. 
(IDEX Health & Science, Oak Harbor, WA) was used to sample from the well plate 
and store the sample droplets.  One end of this tubing was connected to a 100 µL 
syringe (Hamilton, Fisher Scientific, Pittsburg, PA) using a 250 µm bore PEEK union 
(Valco Instruments, Houston, TX).  The syringe and Teflon tubing was pre-filled 
with the immiscible phase and a PHD 200 programmable syringe pump (Harvard 
Apparatus, Holliston, MA) in refill mode was used for sampling.  An in-house built 
xyz-micropositioner (assembled from XSlide
®
 assemblies, Velmex Inc., Bloomfield, 
NY) controlled by a Labview program written in-house (National Instruments, Austin, 
TX) was used to maneuver the inlet of the Teflon tubing and sample from each well.  
An aspiration rate of 1 µL/min was used to form the samples.  Sample plugs were 
measured under a fluorescence microscope when they passed through the field of 




Mircrofluidic Chip Operation   
Before use, chips were conditioned with 0.1 M NaOH in 50:50 (v:v) 
H2O/Methanol by perfusing the solution through separation channels for 10 min.  
Care was taken so that the solution did not go into the hydrophobic channels.  This 
was followed by conditioning channels with deionized water and electrophoresis 
buffer for 5 min each.  Sample cartridges were connected to the chip inlet capillaries 
using 360 i.d. Teflon connectors.  To start sample analysis, both buffer and 
segmented-flow were initiated while cathode reservoir was electrically connected to a 
negative high voltage (–HV) power supply (CZE1000R, Spellman High Voltage 
Electronics, Hauppauge, NY) and buffer waste reservoirs grounded.  Voltage applied 
was controlled by a personal computer equipped with a multi-function board 
(AT-MIIO-16, National Instruments, Austin, TX) using software written in-house. 
 
Fluorescence Detection and Data Analysis   
Fluorescence detection of all separation channels was accomplished by collecting 
time-lapse intervals of fluorescence images using an inverted epi-fluorescence 
microscope (IX71, Olympus America, Inc., Melville, NY) as described before
30
.  
Briefly, light from a 300 W Xe arc lamp (LB-LS/30, Sutter Instrument Company, 
Novato, CA) was passed through a FITC filter cube (Semrock, Rochester, NY) before 
being focused on the chip detection region (Figure 4-1 (d)) with an objective lens 
(Olympus America Inc., Melville, NY).  Fluorescent emission was collected with the 
same objective and detected using an electron-multiplying CCD camera (C9100-13, 
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Hamamatsu Photonic Systems, Bridgewater, NJ).  Images were collected at ~10 Hz, 
stored, and analyzed with Slidebook software (Intelligent Imaging Innovations, Inc., 
Denver, CO).  Fluorescence intensity corresponding to each separation channel was 
extracted from the images to produce parallel electropherograms that were analyzed 




Results and Discussion  
Interface for droplet extraction   
A microfluidic interface was designed and fabricated for extracting aqueous 
sample droplets from a bi-phase segmented flow.  Previously an interface for this 
purpose was fabricated by manually aligning two microfluidic structures of different 
depths under microscope
86
.  The wall of the deeper channel which segmented flow 
passed through was selectively rendered hydrophobic by derivatizing with OTCS.  
Electrophoresis buffer stream flowed through the shallower channel.  It was found 
that it required a combination of channel wall modification and difference in channel 
depths to form a stable oil/aqueous interface.  Otherwise the oil phase would easily 
invade the electrophoretic channel and interrupt with the separation.  A potential use 
of this interface was to serially analyze samples stored in the droplet format.  This 
way all other sample manipulations such as pipetting or injecting could be 
circumvented and the whole process automated.  Only an external syringe pump 
would be required for sample delivery.  In order to obtain higher throughput by 
processing multiple segmented flow streams simultaneously, it would be beneficial to 
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incorporate multiple such interfaces on a single microfluidic device, each interface 
assigned to a separation channel.  However, the difficulty in the aligning step made 
the fabrication of parallel interfaces almost impossible.  In this work, we developed a 
new approach.  We found that geometrical restriction could be created by 
well-controlled isotropic etching.  As shown in figure 4-1 (c), two channels were 
originally 150 µm apart in the photomask.  During wet etching in a buffered 
hydrofluoric acid solution, these two channels would grown in both depth and width 
and eventually connect with each other.  The etching was stopped when the gap 
between two channels was about 5 - 10 µm high (Figure 4-2 (c)).   
 
Transfer of Droplets to Chip   
A key requirement of the system is a suitable method for transferring sample 
plugs stored in Teflon tubing to the glass electrophoresis chip.  For this purpose a 
commercial fitting (Upchurch nanoport) was initially evaluated.  This way the Teflon 
tubing was connected to the microfluidic channel via a 360 µm o.d., 0.5 mm 
depth-access hole.  Nanoports are convenient for fluidic connections when there is 
only one single phase.  However, when used for segmented flow, the large dead 
volume of the access hole underneath the nanoports caused serious problems for the 
stability of the flow.  Droplet coalescence and high cross contamination were 
observed.   
To circumvent this problem, a zero-dead volume connection was made by 
directly connecting a flat-end capillary to the microfluidic channel via an access hole 
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drilled from the side of the chip.  This piece of capillary was pre-treated with OTCS 
and then connected to the droplet-containing Teflon tubing using a home-made Teflon 
connector.  Smooth droplet transferring without any coalescence was achieved using 
this method.  
  To pattern segmented-flow channel with a self-assembled monolayer of OTCS, 
it was found that the flow rate of hexadecane needed to be at least 1/5 of that of OTCS 
solution to prevent any accidental derivatization of the buffer flow channel caused by 
flow fluctuation.  Accidental derivatization could cause oil phase entering buffer 
flow channel and failure of droplet extraction and was detrimental to chip 
performance.  However, a higher hexadecane : OTCS solution ratio would create 
larger underivatized region in the segmented flow channel.  Even though this region 
was found to be essential for droplet extraction, it was also a source of 
cross-contamination.  Therefore, to minimize this region while establish a stable 
aqueous/oil interface, a flow rate ratio (OTCS : hexadecane) of 5 : 1 was used in all 
our experiments.  A short width of the interface was also found helpful in preventing 
flow fluctuation during derivatization probably because the increased flow resistance 
kept OTCS from crossing the interface.  In our design, the width of the interface was 
20 µm in the photomask and 100 µm after etching (see Figure 4-2 (d)).  Decreased 
interface width; however, was not observed to affect efficiency of droplet extraction.  
To further reduce the size of the underivatized region in the segmented flow channel, 
the side access hole was drilled as close as possible to the interface under a 
microscope so that the final length of this region was only about 300 µm (labeled in 
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Figure 4-2 (b)).  
Conditions affecting quality of OTCS derivatization were also studied.  Initially 
we found that even though most interfaces worked for the first few injections, 
performance of a significant portion of units deteriorated with time.  In some cases, 
injection was no longer observed.  By observing droplet extraction at the interface, 
we found that in these cases the aqueous layer in the segmented flow channel no 
longer existed and whole channel was taken over by the immiscible phase.  Even 
though the oil phase did not cross the interface and enter the buffer channel, droplets 
would pass by the interface without being extracted.  Reason for this was ascribed to 
instability of the OTCS/hexadecane interface during channel modification.  This 
caused accidental but incomplete derivatization of the region which was supposed to 
be underivatized.  Therefore the aqueous layer critical to droplet extraction was 
unstable and was gradually expelled by the oil phase.  We found that air bubbles 
were the main cause of unstable flow interface during derivatization.  Purging all air 
bubbles with hexadecane and establishing stable flow before switching to OTCS was 
found to greatly improve the success rate.  In some other cases, peaks in the 
electropherograms gradually became broadened and resolution was lost.  This was 
due to imperfect silane reaction which resulted in large underivatized areas in the 
segmented flow channel.  Droplets would adhere to these areas and then slowly 
merge into the buffer stream thus broadening the injected plugs.  As noted in 
literatures, silane reaction is extremely sensitive to moisture.  To reduce moisture, 
we stored the chip in a desiccator until derivatization.  Also all the solvents used 
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were dried with molecular sieves.  However, even with all these precautions, the 
success rate was only 70%. 
 Separation channels which were 41 µm wide on top and 18 µm deep were 
fabricated on a different glass wafer.  Deeper separation channels were used here 
because they were less prone to clogging when drilling the side access holes.  In 
addition, water was perfused against the direction of the drilling so that most debris 
was flushed out.  Connecting separation channels to the buffer channels was very 
simple and could be easily done with manual alignment under naked eye.  Variation 
of the superimposed area of the two networks was found to have no significant effect 
on sample injection.  Width of buffer flow channel was increased from 180 µm to 
960 µm 1 cm after its interface with the segmented flow channel.  This was found to 
be necessary to reduce the flow resistance after the inlet to the separation channel and 
minimize flow splitting which could compromise CE separation efficiency.  
Detection region was shown in Figure 4-1 (d) where three separation channels 
converged and connected to a common waste channel.  This common waste channel 
had a width of 156 µm on top.  This was found to efficiently prevent separation 
channels from being clogged.  Also higher electric field could be generated along 
separation channels because less voltage was distributed across the waste channel 
(more details in the next part).  
 
Chip performance   
Sample injection control is essential for speed and quality of CE operation and 
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performance.  Several factors such as sample size, flow rate and voltage were 
expected to affect injection and separation efficiency and thus studied in detail.  
Effects of channel modification and cross contamination were also studied.  
1. Effect of interface modification.  Two different modification patterns were 
created and compared.  In figure 4-3 (b), the underivatized region in the segmented 
flow channel extended toward the same direction of segmented flow, while in figure 
4-3 (a), the direction of this region was reversed.  Sample droplet extraction was 
done using interfaces patterned both ways and electropherograms were compared 
(figure 4-3 (c)).  Under the same experiment conditions, the interface in figure 4-3 (b) 
resulted in worse separation efficiency and resolution.  By observing the extraction 
process it was found that this was caused by multiple injections from a single droplet.  
When a droplet reached the interface, a portion of it was extracted into the buffer 
stream but the other half merged into the aqueous layer.  Since this layer was 
relatively stagnant the sample content was not flushed out to the waste.  Instead a 
fraction of this layer would gradually leak into the buffer stream until it returned to its 
original volume.  The result of this was either multiple injections or prolonged 
injection.  Interestingly with interface 4-3 (a) this was not observed and complete 
extraction and clean injection were obtained.  This was probably because in this case 
the aqueous layer acted as a path into the buffer stream which facilitated droplet 
transferring.  Electropherograms showing better resolution were shown in the top 



























Figure 4-3. Two different channel modification patterns for droplet extraction.  
The clear region is modified with OTCS and therefore is hydrophobic.  The dark 
region is underivatized and remains hydrophilic.  (a). The hydrophilic region extends 
toward the inlet of the segmented flow.  Once droplets enter the microfluidic channel 
they immediately merge into this region and are extracted into the electrophoresis 
buffer stream.  A fraction of the droplet is then injected onto the separation channel 
positioned downstream; (b). The hydrophilic region points away from the inlet of the 
segmented flow channel.  Droplet extraction doesn‟t happen until droplets reach the 
interface; (c). Typical electropherograms acquired from interface shown in (a) and (b) 
respectively.  Top panel corresponds to interface (a) and shows better separation 
efficiency while bottom panel from interface (b) has broader peaks and worse 
resolution. 
 
2. Cross contamination.  With the interface shown in figure 4-3 (a), the biggest 
source of cross contamination was the aqueous layer in the segmented flow channel 
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because sample droplets merged into this layer before they enter the buffer stream.  
To minimize the volume of this layer, we have tried to decrease its length during 
fabrication as discussed earlier.  In addition we have found that by supplementing the 
FC-40 with 1% (v/v) perfluoro-1-octanol the oil phase would expand and displace 
part of the aqueous layer thus further decreasing its volume.  To evaluate cross 
contamination, two sample droplets followed by three blank droplets, each was about 
9 nL, were serially analyzed on chip (Figure 4-4).  Cross contamination in this case 
was 7%.  After the first blank droplet, signals from the other two blanks did not drop 
significantly, which indicated that there might be other sources for cross 
contamination.  Also since the source of cross contamination, the aqueous layer, had 
a constant volume, lower cross contamination should be possible if larger sample 
















Figure 4-4. Typical electropherograms showing cross contamination.  Two 
sample droplets containing 65.4 nM rhodamine 110 internal standard and 2 µM BGTP 
in TGEM followed by three blank droplets were extracted and injected.  Each 
droplet was about 9 nL.  Immiscible phase was Fluorinert
®
 FC-40 supplemented 
with 1% perfluoro-1-octanol.  Both segmented flow and buffer flow rates were 4 
µL/min and separation voltage was 6 kV here.  Cross contamination was evaluated 
using rhodamine 110 peak height and was about 7.3%.  
 
3. Effect of sample size.  It was expected that the size of the sample droplet 
should be proportional to amount of injection.  Therefore an optimal sample size 
would be desirable to obtain the optimal combination of signal intensity and 
separation efficiency.  Groups of sample droplets of different sizes were generated 
and then analyzed on chip (Figure 4-5 (a)).  Peak width at half peak height was used 
to evaluate peak broadening.  Determining actual separation efficiency (e.g. plate 
number) was difficult in this case because it was hard to determine to the time when 
90 
injections happened which was required to calculate migration time.  As shown in 
Figure 4-5 (b), peak height increased with droplet size while peak broadening only 
worsened marginally.  These results suggested that for the volumes used, the droplet 














































































Figure 4-5. Effect of sample droplet size on CE separation.  (a). Five groups of 
sample droplets of different sizes were analyzed on chip.  Each group had four 
droplets of the same size as indicated in the figure.  Each droplet contained 65.4 nM 
rhodamine 110 internal standard and 2 µM BGTP in TGEM buffer.  Flow rate was 4 
µL/min and separation voltage was 7 kV; (b). Rhodamine 110 peak heights (squares) 
and peak widths at half peak height (diamonds) were plotted against droplet sizes.  
Peak heights increased with droplet volumes indicating more injection at larger 
volume.  Peak widths at half peak height only increased slightly from 2.2 nL droplets 
to 17.6 nL droplets, which meant that separation efficiency was not lost in this droplet 
size range.  Error bars are ±1 SD and n=4.  
 
 4. Effect of flow rate.  Effect of flow rate of segmented flow on sample injection 
and separation efficiency was evaluated.  Segmented flow rate was varied from 2 to 
5 µL/min while the buffer flow rate was varied accordingly and kept the same as the 
segmented flow.  This way neither of the flow rates would be rate limiting and the 
segmented flow rate would be equal to how fast sample was swept across separation 
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channel inlet.  As could be seen in Figure 4-6 (a), increasing flow rate directly 
resulted in higher injection frequency and thus higher throughput.  Peak intensity 
decreased with increasing flow rate but peak broadening was not affected (Figure 4-6 
(b)).  This result again suggested that the volume injected was not a significant 
contributor to overall bandwidth.  Thus, with this system a trade-off between 
throughput and efficiency could be made by varying sample and buffer flow rates. 
 









































































Figure 4-6. Effect of flow rate on CE separation.  (a). Sample droplets of the same 
size and content were analyzed on chip but with varied flow rates as indicated.  
Three droplets were injected at each flow rate.  Each droplet was about 9 nL and 
contained 65.4 nM rhodamine 110 internal standard and 2 µM BGTP in TGEM buffer.  
Separation voltage was 7 kV; (b). Rhodamine 110 peak heights (squares) and peak 
widths at half peak height (diamonds) were plotted against flow rates.  Peak heights 
decreased with flow rates indicating less injection at high flow rate because sample 
passed by the separation channel inlet at a faster speed which meant less injection 
time.  Peak width at half peak height which is inversely proportional to separation 
efficiency did not change in the flow rate range tested here.  Error bars are ± 1 SD 
and n=3.  
 
 5. Effect of voltage.  Since voltage was kept constant during chip operation, it 
acted as both injection voltage and separation voltage.  Therefore its effect on 
separation efficiency was studied.  As shown in figure 4-7 (a), voltage was varied 
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while other experiment conditions were kept constant.  Four sample droplets were 
electrophoretially analyzed at each voltage.  Intensity of electric field was estimated 
by calculating the ratio of resistance of separation channels and waste channel.  
Since the ratio was about 7.2:1, the electric field was 1 kV/cm when 4 kV was applied 
and 1.8 kV/cm when 7 kV was applied.  As shown in Figure 4-7 (b), peak height 
increased with voltage while the peak broadening increased at first and then leveled 
off probably due to overinjection.  Higher voltage was not tested due to arcing and 













































































Figure 4-7. Effect of separation voltage on CE separation.  (a). Sample droplets 
of the same size and content were analyzed on chip with different separation voltage 
applied.  Four droplets were injected at each voltage.  Each droplet was about 9 nL 
and contained 65.4 nM rhodamine 110 internal standard and 2 µM BGTP in TGEM 
buffer.  Flow rate was 4 µL/min; (b). Rhodamine 110 peak heights (squares) and 
peak widths at half peak height (diamonds) were plotted against voltages.  Peak 
heights increased with voltage indicating more injection.  Peak width at half peak 
height first decreased from 4 kV to 5 kV indicating increased separation efficiency.  





 As could be seen in the discussion above, injection control with the device 
presented here was totally different than previously reported electrophoretic devices.  
In traditional CE instrument, inlet of the capillary is moved between sample vials and 
electrophoresis buffer vial to switch between injection mode and separation mode.  
Voltage control is required for turning on and off power supply during the operation.  
Besides adding complexity to the operation, it also affects the instrument‟s duty cycle.  
Flow-gated CE obviates mechanical control of the CE capillary, but it requires 
additional control (e.g. high-speed solenoid valve) for the gating flow.  CE on chip is 
more simplified and injection is solely controlled by manipulating potentials at 
different reservoirs.  Two injections modes i.e. pinched injection and gated injection 
are most commonly used and electroosmotic flow is main driving force for injection 
control.  At least one power supply and one high-voltage relay are required for 
operation.  With our microfluidic device, samples in droplet format were 
continuously transported onto chip and extracted when they approached the interface.  
An electric field was applied at all time across the separation channels.  When a 
sample droplet was extracted and swept past the inlet of the separation channel a 
fraction of it would be injected for separation.  This way only a syringe pump was 
required for sample introduction.  No external computer program was necessary to 
control the power supply.  This largely simplified the operation of the device. 
 
Parallel Analysis of Segmented Samples   
Our goal was to achieve high sample throughput that might be attractive to HTS 
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applications by electrophoretically analyzing segmented samples in parallel.  One 
way to perform drug screening is to measure end-point reaction extent, i.e. amount of 
product formed or reactant consumed at fixed reaction times.  By including test 
compounds in the reaction, the effect of active compounds can be detected.  We have 
previously developed a CE-based enzyme assay for G protein GTPase activity.  A 
fluorescent GTP analog BGTP was used as the surrogate enzyme substrate in the 
assay and its hydrolysis product BGDP was separated by CE from remaining BGTP.  
BGDP formation was thus used to determine GTPase activities.  By performing the 
assay on chip in parallel, we have demonstrated inhibitor screening for in vitro 
modulator of G protein, RGS protein.  However the overall throughput obtainable 
was limited by the speed of sample introduction.  In this work, multiple streams of 
segmented samples consisting of the assay mixtures were fed to parallel separation 
channels via the interfaces described above to achieve high-throughput and automated 
analysis.   
In an initial test of the system, we evaluated injection and separation stability 
within single unit and reproducibility across three parallel units.  We first tested 
stability of single unit by serially extracting and analyzing droplets containing 65.4 
nM rhodamine 110 and 2 µM BGTP in GTPase assay buffer.  With a unit that 
continuously made 40 consecutive injections, the RSDs of absolute and relative (to 
internal standard rhodamine 110) peak areas of BGDP were estimated to be 15% and 
6% respectively.  We believe that improved derivatization procedures would enable 
longer term operation and lower RSDs.  Glass surface activation using Piranha 
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solution prior to OTCS treatment might improve the derivatization quality
175
.  Other 
surface patterning methods such as photocatalytic patterning
173, 176
 might also turn out 
to be superior even though it requires special equipment such as a mask aligner.   
Reproducibility across three parallel units was also evaluated.  Sample droplets 
of the same size (9 nL) and content (65.4 nM rhodamine 110 and 2 µM BGTP) were 
analyzed at flow rate of 5 µL/min and voltage of 7 kV.  Absolute peak area had high 
variation across three channels.  RSD of R110 peak area was as high as 29% and 
BGDP 30%.  Relative BGDP peak area to R110 was more suitable for quantification.  
Average relative BGDP peak areas from three units had an rsd of 2%.  One-way 
ANOVA test showed that measurements by the three units were not significantly 
different from each other.   
To demonstrate high throughput analysis of enzyme reactions for the purpose of 
HTS, 100 nM Gαo was incubated with 2 µM BGTP for 0, 15 and 30 minutes at room 
temperature.  Three cartridges were generated each containing 40 9 nL droplets of 
one of the three quenched reaction mixtures.  Content of all three cartridges was 
pumped out at 4.5 µL/min to chip for separation at a voltage of -7 kV.  Figure 4-8 
shows the typical parallel electropherograms.  Each separation took 15 seconds and 
120 samples were analyzed by CE within 10 minutes.  Different levels of BGDP 
formation could be observed in the inset on the right.  The throughput achieved here 
was equivalent to 720 samples/hr or 17,280 samples/day.  We envision that even 
higher throughput could be achieved with more channels; however, fabrication 




























Figure 4-8. Parallel analyses of segmented samples.  100 nM Gαo was incubated 
with 2 µM BGTP in TGEM buffer at room temperature for 0, 15 and 30 minutes 
before the reactions were quenched by spiking in 10 µM GTP.  40 droplets, each 
having a volume of 9 nL, were generated from each reaction mixture and stored in a 
150 µm inner diameter Teflon tubing.  Gap between two neighbor droplets was about 
1.42 µL of immiscible phase.  All three sets of samples were analyzed 
simultaneously at 4.5 µL/min.  -7 kV was applied for separation.  10 minutes 
analysis time was used to analyze all 120 samples.  Different hydrolysis extent 
indicated by various BGDP peak heights could be observed in the close-up on the 
right.   
 
Conclusions 
We developed a microfabricated world-to-chip interface which coupled streams 
of segmented nanoliter samples to on-chip CE separation.  Multiple such interfaces 
could be integrated on a single device which further increased the throughput.  Chip 
operation required no sample pipetting and external control program and thus was 
highly automated.  CE separation of discrete samples containing GTPase assay 
mixtures was demonstrated and throughput of 720 samples/hr was obtained.  Despite 
the high throughput, life time of the device which was limited by the stability of the 
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modified channel wall remained to be improved.  Also higher separation efficiency 
which is desirable when analyzing more complex samples might require more 
sophisticated sample injection control.  One possible way to do so is to use 
fluorescence-activated voltage control.  Fluorescence from a sample droplet will 
trigger a lower voltage for sample injection.  A higher voltage will then be applied 




RAPID ANALYSIS OF SAMPLES STORED AS INDIVIDUAL PLUGS IN A 
CAPILLARY BY ELECTROSPRAY IONIZATION MASS SPECTROMETRY 
AND APPLICATION IN HIGH-THROUGHPUT LABEL-FREE ENZYME 
INHIBITOR SCREENING 
Reproduced in part from (Pei, Li et al. 2009). Copyright 2009 American Chemical Society. 
 
Introduction 
Drug discovery often requires identification of lead compounds from 
combinatorial libraries containing millions of candidates.  High-throughput 
screening (HTS) is necessary for such large scale sample handling and 
measurement
177
.  In vitro biochemical assay in multi-well plates with optical 
detection
178-181
 has been the primary format for HTS.  A drawback of optical 
detection is that usually either labels or indicator reactions must be incorporated into 
the assay to generate detectable signal.  This requirement results in several problems 
including increased difficulty of developing the assay, increased cost because of 
added or complex reagents, and greater potential for inaccurate results if test 
compounds affect the label or indicator reaction rather than the test reaction.  
High-throughput assays that can be performed without labels or indicator reactions 
are therefore of great interest
182
.   
A potentially powerful label-free detection system is electrospray ionization 
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mass spectrometry (ESI-MS).  Indeed, a variety of ESI-MS assays for enzymes and 
non-covalent biomolecule binding have been developed and explored for screening 
applications
182-184
.  The throughput achievable by ESI-MS is limited by the need to 
interface the mass spectrometer to multi-well plates and perform individual injections 
for each assay.  (This limit assumes the standard procedure of testing one compound at 
a time.  For certain assays, MS can analyze a mixture of test compounds at one time
96, 
102
).  Currently, individual samples are most often introduced to a mass spectrometer 
by flow injection, i.e. loading sample into an HPLC-style injection valve and then 
pumping it through the ESI emitter.  It is a significant challenge to engineer a rapid 
injection system that uses small volumes, has low carry-over between injections, uses 
low flow rates, and is reliable.  A rapid system that requires just 4-5 s per analysis and 
consumes 1-5 microliters of sample has been commercialized
185
; however, more 
common systems are considerably slower, having an average speed of 5-10 
min/sample.     
In this work, we forwent flow injection and utilized segmented flow analysis for 
high-throughput ESI-MS.  Segmented flow has long been a popular method for 
high-throughput analysis in clinical settings
168
.  In the classical scheme, individual 
samples are segmented by air in a tube, reagents added for colorimetric or fluorescent 
assays, and the samples passed through an optical detector
168, 169
.  The last few years 
have seen a resurgence of interest in segmented flow with the advent of sophisticated 
microfluidics that allow miniaturization (femtoliter to nanoliter samples) and new 
methods for manipulating droplets
73, 91
.  The sophistication of these methods has 
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rapidly increased so that it is now possible to perform many common laboratory 











 on plugs in microfluidic systems.  A frequent emphasis is that such 
manipulations can be performed automatically at high-throughput.  A limiting factor 
in using and studying multi-phase flows is the paucity of methods to chemically 





 are most commonly used.  Systems for electrophoretic analysis of 
segmented flows have also been developed
85, 86
.  Drawbacks of these methods are 
that they require that the analytes be labeled to render them detectable and they 
provide little information on chemical identity of plug contents.  NMR has been used 
for analysis of plugs, but poor sensitivity of this method limits its potential 
applications
89
.  Mass spectrometry has been coupled to segmented flow by collecting 
samples onto a plate for MALDI-MS
82
 or a moving belt interface for electron impact 
ionization-MS
187
.  ICP-MS of air-segmented samples has been demonstrated on a 
relatively large sample format (0.2 mL samples)
188
.  MS analysis of acoustically 
levitated droplets using charge and matrix-assisted laser desorption/ionization has also 
been demonstrated
189
.  Recently, a method to perform electrospray ionization 
(ESI)-MS of a stream of segmented flow has been reported
87
.  In this method, a 
stream of aqueous droplets segmented by immiscible oil was periodically sampled by 
using electrical pulses to transfer the droplet into an aqueous stream that was directed 
to an electrospray source.  This proof-of-concept report showed the feasibility of 
on-line droplet analysis; however, the limit of detection (LOD) for peptide was ~500 
101 
µM.  The high LOD was due at least in part to dilution of droplets once transferred 
to the aqueous stream and the high flow rate (~3 L/min) for the electrosprayed 
solution.  The dispersion of droplets after transfer to the aqueous stream also limited 
the throughput of this approach. 
We have found that a cartridge of 10 to 50 nL samples segmented by gas 
within a Teflon tube can be pumped directly into a electrospray source to yield a 
simple, robust and sensitive method for analyzing droplet content.  This method can 
also be considered a novel approach to sample introduction for MS.  As a test system 
we demonstrate screening for inhibitors of acetylcholinesterase (AchE).  AchE 
catalyzes conversion of acetylcholine (Ach) to choline and is the primary way of 
terminating Ach signaling at synapses.  Inhibition of AchE is a possible treatment for 
Alzheimer‟s disease (AD) and other related dementia
55-57, 59
.  While a handful of 
AchE inhibitors have been approved for AD treatment, searching for compounds with 
improved pharmacological and toxicological properties remains an active pursuit
60-63
.  
Because the AchE reaction does not generate components that are easily detected 
optically, screening has required coupling the enzyme with indicator reactions
64-68, 71
. 





 to directly detect substrate and/or product of the reaction.  
Throughput of 0.2 Hz with 1-5 µL of sample consumption was possible when using 
an automated sampling and injection
72
.  In this work, we demonstrate that with direct 
ESI-MS of segmented flow, we can generate an analysis rate of 0.65 Hz while 




Chemicals and Reagents   
Water and methanol were purchased from Burdick & Jackson (Muskegon, MI).  
Acetic acid was purchased from Fisher Scientific (Pittsburgh, PA).  All other 
chemicals were obtained from Sigma. 
 
AchE Activity Measurement  
10 mM NH4HCO3 was used as reaction buffer for all AchE experiments.  AchE 
(from Electrophorus electricus, Type VI-S) was prepared daily from lyophilized 
powder at 90 µg/mL solution.  2 µL solution of drug to be tested was mixed with 20 
µL AchE solution and incubated on ice for 30 min before being brought to room 
temperature.  20 µL 200 mM acetylcholine iodide solution was then added to above 
AchE solution to start hydrolysis.  After incubation, 180 µL of an ice-cold mixture 
containing 1 mM chlormequat, 60% (v/v) methanol and 1.5% (v/v) acetic acid was 
then rapidly mixed with 20 µL of the enzyme mixture to terminate the reaction.    
30 µL of each final quenched reaction mixtures were pipetted into a 384-well plate 
(Corning, Fisher Scientific, Pittsburg, PA) for loading into sample tube for analysis.  
   
Sample Droplet Generation   
Air-segmented sample droplets were generated using the system illustrated in 
Figure 5-1 A.  A Teflon tube of 75 µm inner diameter (i.d.) and 360 µm outer 
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diameter (o.d) (IDEX Health & Science, Oak Harbor, WA) was used for sampling and 
storing sample plugs.  One end of this tubing was connected to a 100 µL syringe 
(Hamilton, Fisher Scientific, Pittsburg, PA) using a 250 µm bore PEEK union (Valco 
Instruments, Houston, TX).  The syringe and Teflon tubing were intially filled with 
Fluorinert
®
 FC-40 (Sigma).  The syringe was mounted onto A PHD 200 
programmable syringe pump (Harvard Apparatus, Holliston, MA).  To fill the tube 
with air-segmented samples, a computer-controlled xyz-micropositioner (assembled 
from XSlide
®
 assemblies, Velmex Inc., Bloomfield, NY) was used to move the inlet 
of the Teflon tubing from sample-to-sample on the multi-well plate while the pump 
was operated at a fixed aspiration rate.  By using an aspiration rate of 200 nL/min, 
10 nL sample plugs and 4 mm long air plugs were produced.  Using this procedure, a 
tube could be filled with 100 samples in ~10 min.  The relative standard deviation of 
sample plug size was 25%.  It was also observed that FC-40 formed a thin film 
covering the tubing wall and this was found to help decrease droplet-to-droplet carry 
over.  Figure 5-1 B and C compared droplets generated with and without FC-40 





























Figure 5-1. Generation of air-segmented sample plugs.  A. Scheme showing 
generating air-segmented sample droplets from a multi-well plate. Cartridges of 
sample droplets were prepared by dipping the tip of a 75 µm i.d. Teflon tubing 
prefilled with Fluorinert FC-40 into sample solution stored in a multi-well plate, 
withdrawing a desired volume, retrieving the tube, withdrawing a desired volume of 
air, and moving to the next well until all samples were loaded. Movement of the 
tubing was controlled with an automated micropositioner and sample flow was 
controlled with a syringe pump connected to the opposite end of the tubing; B. 
Photograph of a 3 mm long (50 nL) plug stored in a 150 m i.d. Teflon tube.  Plug 
was created by withdrawing sample and air alternately into the tube prefilled with 
Fluorinert FC-40. Cross contamination was less than 0.1% in this case; C. Same as B 
except the tube was prefilled with air instead of oil.  Cross contamination could be as 




ESI-MS and Data Analysis   
After sample plug generation, the inlet end of the Teflon tubing was connected to 
a Pt-coated fused-silica electrospray emitter (FS 360-50-8-CE, New Objective, 
Woburn, MA), which was 50 µm i.d. and pulled to 8 µm i.d. at the tip, using a 360 i.d. 
Teflon connector (Figure 5-2 A).  The emitter was mounted in a nanospray source 
(PV-550, New Objective).  Sample plugs were pumped at 1.0 µL/min using a syringe 
pump through the emitter poised at +1.7 kV for ESI-MS analysis.  Electrospray 
plume could be seen when sample droplets arrived at the emitter tip (Figure 5-2 B) 
while there was no signal when air plugs exit (Figure 5-2 C).  The MS used was a 
LTQ XL linear ion trap MS (Thermo Fisher Scientific, Waltham, MA) operated in 
single-stage, full-scan mode with following settings: automatic gain control (AGC) on, 
negative mode, 50 – 300 m/z scan range and micro scan number = 1.  Scan time was 
approximately 0.1 s. Reconstructed ion current traces (RIC) of choline (m/z 104) and 
chlormequat (m/z 122) were extracted from total ion current (TIC).  Peak marking 















Figure 5-2. Direct ESI-MS analysis of air-segmented samples.  A. Overview of 
scheme for analyzing a train of plugs stored in the Teflon tube.  +1.7 kV is applied at 
the spray tip.  Connector is a Teflon tube that fits snugly over the cartridge tube and 
emitter tip; B. A picture showing the electrospray plume when sample is emerging; C. 
A picture showing no electrospray when air is emerging. 
 
Results and Discussion 
Acetylcholinesterase assay   
Initial experiments were directed at determining AchE assay conditions that 
would be compatible with ESI-MS.  Incubating acetylcholine with AchE in 10 mM 
NH4HCO3 buffer for 20 min at room temperature followed by quenching of the 
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reaction by addition of a methanol and acetic acid mixture was found to be suitable.  
With this incubation time, less than 10% of the original acetylcholine was consumed 
thus ensuring linear hydrolysis rates.  The quenching solvent was found to 
completely stop the enzymatic reaction and be compatible with MS.  NH4HCO3 
provided adequate buffering while being compatible with ESI and providing low ion 
suppression.  To improve quantification, chlormequat was included in the quenching 
solution to act as an internal standard
71
.  Typical MS spectra illustrating detection of 
substrate (acetylcholine), product (choline), and internal standard are shown in Figure 
5-3.  Under the electrospray conditions used, the spectra are free from interfering 
peaks from the Fluorinert
®
 FC-40 used for coating the Teflon tubing.  Inhibitors 
added to the assay reduced the choline signal as shown by Figure 5-3 A.  
 































Figure 5-3. Typical mass spectra of AchE assay.  Analysis of quenched AchE 
assay mixtures after incubating 100 mM acetylcholine with 45 µg/mL AchE with or 
without 100 µM neostigmine at room temperature for 20 minutes.  Mass spectra 
showing inhibited (A) and basal (B) AchE activities.  Compared to the basal 
spectrum, choline (m/z 104) production from hydrolyzing acetylcholine (m/z 146) is 
decreased and shows smaller MS intensity. 
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Rapid Screening   
To demonstrate rapid screening of AchE inhibitors, a set of 32 compounds 
including 4 known AchE inhibitors and 28 randomly picked compounds were tested at 
100 µM each in the AchE assay mixtures.  For screening, each compound was tested 
in triplicate resulting in a total of 102 samples (96 assay samples, plus 3 blanks with 
no enzyme added, and 3 controls with no test compound added).  These samples 
were loaded into a Teflon tube as a linear array using the procedure described in the 
Experimental Section.  Throughput of analysis is determined by sample plug volume 
and flow rate into the ESI source so that small sample volumes and high flow rates 
generate higher throughput.  For this work, 10 nL sample plugs with 17 nL air gaps 
(or 4 mm spacing in a 150 µm i.d. tubing) were chosen as a small volume that was 
convenient to produce.  Samples were pumped through the emitter at 1 µL/min, 
which was the highest flow rate that did not cause the samples to merge in the emitter 
tip because of compression of the air segment.   
These conditions allowed the 102 samples to be analyzed in 2.6 min, 
corresponding to an analysis rate of 0.65 Hz, as illustrated by ion current traces for the 
analysis shown in Figure 5-4 A.  Each sample was detected as a current burst 
followed by a period of zero current corresponding to the air segment passing through 
the emitter.  As shown, the current rapidly stabilized for each sample and remained 
steady as the sample passed through the emitter.  The presence of inhibitors was 
easily visualized by the reduced choline signal relative to internal standard signal in 
these traces.  The inconsequential carry-over between samples was illustrated by the 
109 
immediate step change in signal between samples of different choline concentrations.  
The throughput of the segmented flow method compares favorably to 
previously reported flow injection AchE assays
65, 67, 72
.  The speed of these methods 
was limited by the need to inject individual samples or additional separation steps 
when assay buffer was not directly compatible with ESI-MS.  Other approaches for 
ESI-MS analysis of droplet or segmented flow samples have also been reported
87, 88
.  
These methods involve using microfluidics to extract the aqueous sample from an oil 
stream and transferring to a secondary aqueous stream before passing through the ESI 
emitter.  The resulting band broadening and carry-over effects would likely keep 
throughput from being as good as that reported here.   
Further improvements in throughput using the method reported here are 
feasible.  One way is to generate smaller samples segmented by smaller air gaps by 
using smaller i.d. sample tubing and more sophisticated positioner that can move 
faster from well to well.  This would be able to decrease the time required to analyze 
each sample.  Higher flow rates may be possible by using fluorocarbon oil to 
segment samples to avoid the effect of air compressibility.  Ultimately the analysis 


















































































Figure 5-4. Screening of AchE inhibitors by droplet-ESI-MS.  A. 32 compounds 
were tested for their activity toward AchE.  Each compound had three replicates. 102 
sample droplets were generated including these 32 compounds (96 droplets) and two 
controls (6 droplets).  RICs of choline and clormequat from analyzing all 102 sample 
droplets in 2.5 min.  Compounds tested from left to right were control 1 (no drug 
added), malathion, neostigmine, eserine, edrophonium, isoproterenol, yohimbine, 
UK14,304, DMSO, serine, adenosine, thyronine, GABA, phenylalanine, alanine, 
proline, arginine, cysteine, lysine, tyrosine, glycine, arginine, glutamine, methionine, 
leucine, tryptophan, isoleucine, histidine, glutamic acid, aspartic acid, taurine, 
dopamine, valine, control 2 (no enzyme added); B. After subtracting the background 
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choline, choline formation was calculated from the three replicates for each 
compound. 
 
Quantification   
To quantify choline production in the enzyme reaction, four different 
measurements were evaluated as shown in Figure 5-5 A.  Absolute choline peak area 
had the most variability which was not surprising because the size of sample plugs 
had 25% variability.  Peak heights were less variable but could sometimes be 
affected by fluctuation in electrospray stability.  Choline peak area and height 
relative to the internal standard had low variability and both proved to be equally 
acceptable for quantification.   
Charge competition between choline and internal standard chlormequat during 
electrospray and its effect on quantification was also evaluated.  Choline signal 
intensity was measured at various choline concentrations with a fixed chlormequat 
concentration.  As shown in figure 5-5 B, choline signal increased with its 
concentration non-linearly while chlormequat signal decreased with increasing 
choline concentration.  By using choline signal relative to the internal standard, a 
linear calibration curve could be obtained demonstrating that the use of internal 
standard also helped to correct for charge competition during ESI at different choline 
concentrations. 
Figure 5-4 B summarizes quantification of the assay screen shown in Figure 
5-4 A using peak area ratio for choline and internal standard.  Four of the known 
AchE inhibitors showed reduced choline production as expected.  Interestingly, 
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isoproterenol and DMSO also showed some inhibition at this concentration.  DMSO 
increased signal of both choline and chlormequat; however, quantification was not 
affected since relative signal intensities were used.  This result indicates that the 
assay should be resistant to compounds that have generalized effects on the ESI-MS 
process.  The reproducibility of the assay can be evaluated using the Z‟-factor
45, 121
.  
Z‟-factor is defined as RssZ posneg /)(0.3(0.1'   where sneg is the standard 
deviation of the response of a negative control (no inhibitor) and spos in the standard 
deviation of the response of a positive control (with inhibitor) and R is the difference 
in signal between the mean of positive and negative controls.  Z‟ over 0.5 is 
generally considered necessary for HTS.  Z‟ values in experiments for neostigmine, 
eserine, malathion and edrophonium were 0.84, 0.83, 0.87 and 0.85 respectively.  
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Figure 5-5. Quantification of AchE hydrolysis.  A. Evaluating quantification of 
choline formation by four parameters: peak height is the highest choline ion intensity 
of all the scans over a sample droplet; relative height is the ratio of peak height of 
choline to that of chlormequat; peak area is the area under all the MS scans of a 
sample droplet; relative area is ratio of the peak area of choline to that of chlormequat.  
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Relative standard deviations of these four parameters from 7 separate experiments 
were used to generate the above figure.  The average RSDs were 5.9%, 28.5%, 1.9% 
and 1.5% for calculation based on peak height, peak area, relative height and relative 
area respectively (n=7); B. Calibration curve for choline. Solutions containing 0.9 
mM chlormequat and various concentrations of choline (200 µM to 10 mM) were 
infused for ESI-MS analysis.  Choline peak intensity increased with its concentration 
non-linearly while chlormequat peak intensity decreased with higher choline 
concentration.  Using ratio of the two peak heights corrected the effect caused by 
charge competition during electrospray ionization and the ratio increased linearly with 
choline concentration. The calibration curve had a slope of 0.1083 (mM
-1
) and a y 




AchE inhibitor characterization   
Another use of the assay is for rapid determination of dose-response relationships 
for known inhibitors as illustrated for neostigmine, eserine, malathion, and 
edrophonium in figure 5-6.  For this experiment, 10 different concentrations of each 
inhibitor ranging from 10 mM to 0 nM were incubated with the assay mixtures for  
20 min at room temperature.  The quenched reaction mixtures were analyzed as 
described earlier and absolute choline formation was derived from the choline 
calibration curve.  Three replicates were taken for each inhibitor concentration.  
IC50s of eserine, malathion and edrophonium were calculated to be 63 ± 13 nM, 480 ± 
70 µM, 63 ± 11 µM respectively.   Neostigmine resulted in two IC50 values, 50 ± 25 
µM and 38 ± 10 nM, based on two-site competition fitting.  These number generally 
agreed well with previously reported values( eserine 72-109 nM
190
,  malathion 370 
µM
191
, neostigmine 11.3 nM
192
 and edrophonium 5.4 µM
193
).  However, direct 
comparison of these numbers might not be appropriate because the experiment 
conditions were not identical (e.g. use of surrogate substrate and different AchE).  
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Figure 5-6. Dose-response curves of four AchE inhibtors: neostigmine, eserine, 
malathion, and edrophonium.  Choline formation when incubated with various 
inhibitor concentrations were fit to sigmoidal dose-response curves except for 




 We demonstrated that AchE inhibitors could be screened at throughput of 1.5 
s/sample by preparing samples as individual nanoliter plugs segmented by air and 
rapidly analyzing them using ESI-MS serially.  The throughput achieved here 
showed a significant improvement over other screening methods since it did not 
require flow injection of individual samples.  Higher throughput is possible by 
analyzing smaller sample droplets at higher flow rates.  Another advantage of 
segmented flow analysis relative to flow injection approaches is the low sample 
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volume requirement.  Only 10 nL of sample was consumed in this assay because 
there was no need to fill and rinse an injection loop.  Of course, the total sample used 
depends on the volume required to collect the 10 nL sample.  In principle it should 
be possible to aspirate sample from much lower volume wells than used here.     
Although our experiments illustrated the possibility of rapid analysis of assay 
mixtures by MS, a complete HTS system would require consideration of all aspects of 
the screen for high-throughput.  For example, in the present experiments the overall 
throughput was limited by loading of samples into the tube for assay.  Parallel 
loading of tubes and higher flow rates during loading are approaches that may be used 
to improve throughput of this aspect of the method.  Alternatively, since only a 
fraction of the assay mixture was consumed the entire assay approach could be 
performed in droplets.  Several tools for manipulating droplets have been published 
including mixing with streams, reagent addition, and splitting
76, 78, 81, 91, 186
.  Thus, it 
is possible to envision a system in which a chemical library is stored as a series of 
droplets that are then tested and assayed by MS and bypass the transfer from 
multi-well plate to tubing.   
Another consideration in overall throughput is sample preparation.  The Ach 
assay was compatible with ESI; however, some assays may require desalting or 
extraction prior to analysis.  Development of such methods that are compatible with 
multi-well plates or with the segmented flow will be required to further expand the 




In this dissertation, we introduced two approaches to HTS.  In the first approach 
we escalated the throughput of a CE-based fluorescent enzyme assay by performing 
fast and parallel CE separation.  In the second approach, MS was exploited for HTS 
owing to its fast scanning speed and universal detection capability.  One feature 
shared by these two approaches was the distinct sample introduction method.  
Instead of pipetting and injecting individual samples, which can be labor-intensive 
and time-consuming, samples were introduced as a train of droplets segmented by an 
immiscible phase.  This way samples were fed to either CE or MS sequentially 
without additional sample handling or transferring.  The achieved throughput was 
only limited by the speed of the analyzer.   
While these two approaches showed promises for HTS applications, additional 
features such as on-line reagent addition and reaction, if added to the already 
developed techniques, could further automate the HTS operation.  Also with 
appropriate modifications to the analytical systems presented herein, we could 
envision other interesting applications.  All these possible routes are discussed in the 
next few sections.  
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On-line in-droplet enzyme reactions 
In the experiments presented in chapters 2-5, enzyme assays including reagent 
mixing, incubation and quenching were performed offline.  When used in HTS, 
offline assay format is compatible with how test compounds are currently stored in 
multi-well plates.  Reagent mixing and reactions can take place on plate.  This is 
convenient for direct on-plate readout such as using fluorescence plate reader; 
however, an additional droplet generation step is required if either of the herein 
developed methods is to be used.  We envision that combinatorial compounds can be 





 have been demonstrated, it will be extremely convenient and 
attractive to incorporate these operations on-line to achieved automated operations 
(Figure 6-1).  This way enzyme and substrate can be mixed with individual test 
compounds sequentially and incubation will take place in droplets.  Incubation time 
can be easily adjusted by either controlling the flow rate of the segmented flow or 
adjusting the tubing length after the second T-junction.  Quenching reactions is no 
longer necessary because essentially all droplets should have the same incubation 
time.  Figure 6-1 illustrates one possible scheme of such on-line ESI-MS-based 
screening assay.   With this system, we can envision fully automated screening with 










Figure 6-1. On-line droplet-based enzyme assay and MS analysis.  A 
peristaltic pump is used to draw plugs of test compounds (compounds can also be 
pre-stored in the tubing as the compound library) from well plates.  Enzyme and 
substrate solutions are mixed on-line with the drugs via two T-connectors.  After 
some incubation time, individual droplets consisting of the assay mixture are 
analyzed by ESI-MS.  
  
Screening using immobilized micro-enzyme reactors 
Another alternative to on-line reagent mixing is to immobilize enzymes on the 
microfluidic channels to form micro-enzyme reactors (Figure 6-2).  When droplets 
containing substrate and test compounds pass through the enzyme reactor, the 
substrate would be turned over.  The reaction product is then detected by 
downstream analyzer (e.g. CE separation as shown in Figure 6-2).  Advantages of 
using immobilized enzyme reactors include minimized enzyme consumption, 
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separation channel
 
Figure 6-2. Microchannel enzyme reactor for droplet-based enzyme assay.  
An immobilized enzyme region (the reactor) is constructed before the 
droplet-to-CE interface described in Chapter 4.  Substrate in the droplets are 
turned over when passing through the reactor and reaction product is separated 
from substrate by CE.  
 
Single-cell analysis in droplets 
 Chemical analysis in single cells is of interest for proteomics and metabolomics 
studies.  Due to the small volume of single cells and low concentration of 
intracellular chemicals, such analysis is difficult.  One of the hurdles is that dilution 
after cell lysis makes the already low-concentration cellular components harder to 
detect.  By encapsulating and lysing single cells in droplets, dilution can be 
minimized and molecules released from the cells can be more easily detected.  In 
fact this has been reported by Chiu‟s group
195
.  In their work, single-cell enzyme 
assay was performed in droplet and activity of intracellular β-galactosidase was 
detected by a fluorescence detector.  It can be envisioned that more comprehensive 
chemical analysis can be achieved by using CE or MS or even CE-MS as the analyzer.  













Figure 6-3. Single-cell analysis in droplets. Three steps are incorporated in this 
scheme.  First the cells are encapsulated in individual droplets using a flow focusing 
device; the cells are then lysed using high electric field
196
; released cellular 
components remain trapped in droplets and are analyzed by CE (or MS). 
 
LC fraction collection coupled to second-dimension separation 
Fraction collection of LC effluent has been practiced extensively.  Collected 
fractions are subjected to all sorts of post-separation analysis such as protein digestion, 
derivatization and a second-dimension separation step.  For HPLC fraction 
collection can be assisted by commercial fraction collector; however for nano-LC, 
which is used for analyzing limited amount of samples, fraction collection can be 
difficult and impractical.  We have shown that resolved bands in a nano-LC 
separation can be collected and stored in discrete droplets using a T-junction shown in 
Figure 6-4 A.  This way LC resolution is preserved as segmented flow and 
post-analysis can be decoupled from LC separation.  Droplet splitting can be used to 
further divide droplets so that each droplet can be analyzed with different methods 
(e.g. CE and MS) and results can be correlated (Figure 6-4 B).  It is also possible to 
perform so-called retrospective analysis where the first halves of the droplets are to be 
analyzed rapidly and only those fractions of interest in the second halves are selected 
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for detailed analysis which usually takes more time.  For example peak parking can 
be used for perform tandem MS on collected droplets for structural identification etc.  
A derivatization step can also be incorporated after collecting LC effluent and before 
further analysis (Figure 6-4 C).  Appropriate derivatization agents can be used to 



















Figure 6-4. LC fraction collection and post-separation fraction processing.  A. 
Effluent from LC separation is fractionized and collected as individual droplets using 
a T-junction.  Droplets are stored in a tubing for later analysis; B. droplet splitting is 
used to produce two identical cartridges containing the LC fractions; C. derivatizing 
agent is added into previously collected droplets using a T-junction. 
 
Droplet-based LC separation/desalting 
 We have demonstrated droplet analysis using CE and MS; however, LC is also of 
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interest to be applied to droplet analysis.  One potential application of a LC 
separation step is desalting.  Biological samples such as microdialysate and cell 
extract contain large amount of inorganic salts which can interfere with ESI by 
causing ion suppression.  Generating a series of droplets as illustrated in Figure 6-5 
and passing them sequentially through a reverse-phase packed column can be used for 
sample desalting and improve MS sensitivity.  Difficulties of this project might 













Figure 6-5. Droplet-based LC separation for desalting.  A sample droplet, a wash droplet and 
an eluting solution droplet are pumped through a reverse-phase packed column sequentially.  The 
outlet of the column is connected to a ESI emitter tip for ESI-MS analysis.
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